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The discovery of CRISPR-Cas9 and development of related technologies promised a 
much more accurate and easier to use method of genome editing. Amidst the research 
fervour prompted by this discovery, some Korean bioscientists are arguing that the 
Korean Bioethics and Safety Act imposes excessive limitations on gene therapy 
research. Calling for deregulation at the 112nd Roundtable Discussions, a policy 
discussion hosted by the Korean Academy of Science and Technology, three of these 
bioscientists presented their arguments. Interestingly, some arguments utilized 
naturalness as a moral value, which stands in contrast to the expected scepticism 
towards assigning value on naturalness. Following the line of thought presented by 
Daston and Vidal in The Moral Authority of Nature, this paper studies the naturalness-
based arguments presented by scientists at the 112nd Roundtable not in their own but 
as a window to their other arguments, their position in relation to the debate, and what 
moral imperatives their position is based upon. Scientists at the Roundtable used their 
scientific expertise to argue for the naturalness of their proposed gene therapy, and 
argued that only science could provide proper answers to questions of naturalness, 
adopting a supposedly moral argument to support the imperative of scientific research. 
This paper argues that a “Q&A relationship” is being established by the scientists 
between themselves and the public, which I believe suggests a shift, but not a break, 
from a simplistic top-down relationship dictated by the deficit model. 
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1. Introduction: Biotech, Nature, and a Policy Discussion 
Since its discovery and announcement by Jennifer Doudna in 2012, the applicability 
of CRISPR-Cas9 to genome editing has been hailed as one of the most important 
breakthroughs in the history of genome engineering. A family of DNA sequences that 
serve a role in the genetic “immune system” of certain species of prokaryotes, used 
for fighting off unwarranted changes in the genome by viruses, Cas9 (CRISPR-
associated protein 9) is an enzyme incorporating CRISPR that uses the CRISPR 
sequence to identify and cleave invasive DNA; Doudna and her team discovered that 
Cas9 could be re-targeted by changing the sample sequence, which meant that any 
DNA sequence could be severed with Cas9 by simply reprogramming the enzyme.1 
Highlighting its ease of replication and its highly specific and programable targetability, 
scientists such as the discoverer Doudna herself have noted from early on the utility 
of CRISPR to biotech applications, including human gene therapy.2  
 While the scientific community hails the development of CRISPR and its 
ability to open doors, they are faced with detractors of genome engineering trying to 
fight its popularization, issuing warnings about the dangers both present and potential. 
The response of scientists to this opposition has primarily been to refrain from 
pursuing the most controversial directions of research while seeking government 
                                                 
1  Martin Jinek, Krzysztof Chylinski, Ines Fonfara, Michael Hauer, Jennifer A. Doudna, and 
Emmanuelle Charpentier, "A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive 
Bacterial Immunity," Science 337, no. 6096 (2012), pp. 816-821. 
2 Martin Jinek, Alexandra East, Aaron Cheng, Steven Lin, Enbo Ma, and Jennifer Doudna, "RNA-
Programmed Genome Editing in Human Cells." elife 2 (2013), e00471. 
Jennifer Doudna, "Perspective: Embryo Editing Needs Scrutiny," Nature 528, no. 7580 (2015), p. S6. 
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approval for other, arguably safer subjects. The 2015 International Summit on Human 
Genome Editing, a meeting between leading bioscientists from around the globe 
organized by the US National Academy of Sciences, Engineering, and Medicine, was 
convened primarily to achieve consensus among the scientist community on what 
directions were dangerous and what were not.3 The conclusions of the International 
Summit were then used to compile a set of policy recommendations for future 
governance of science. 4  In turn, scientists began directing their efforts towards 
directions green-lit by the Summit such as genome editing research on non-viable 
human embryos (those that cannot result in birth), expecting that their research will 
not be met with excessive controversy in light of the encouragement by international 
consensus.5 
 The 2015 Summit was not unique; there were other consensus-forming 
activities throughout the history of biotechnology, typically proceeded by a call to 
moratorium on research until questions on controversial topics can be answered. The 
earliest and archetypical of these was the 1975 Asilomar conference, which was 
convened in light of potential dangers that could arise from genetically modified 
bacteria created in labs, and produced a guideline on proper safety and containment 
                                                 
3 National Academy of Sciences, Engineering, and Medicine, International Summit on Human Gene Editing: 
A Global Discussion (Washington, DC: The National Academies Press, 2016), 
https://doi.org/10.17226/21913. 
4 National Academy of Sciences, Engineering, and Medicine, Human Genome Editing: Science, Ethics, and 
Governance (Washington, DC: National Academies Press, 2017), doi: https://doi.org/10.17226/24623. 
5 Ewen Callaway, "Embryo-Editing Research Gathers Momentum: Scientists Proceed with Human-
Genome-Editing Experiments as Ethical Debate Continues," Nature 532, no. 7599 (2016), pp. 289-291. 
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procedures in handling these engineered organisms.6 As noted by historian of science 
Susan Wright in her work Molecular Politics, Asilomar is remembered by scientists as a 
landmark event that successfully met and answered the concerns of the public while 
providing scientists with time and means to learn more about genome modification, 
which led to the rational deregulation of biotechnology based on new knowledge 
regarding the safety of bioengineering. Due to the events following the Asilomar 
conference and later consensus emulating Asilomar, Genome Engineering is seen by 
scientists, government officials, and NGO activists as a scientific field that has a highly 
conscious relationship with public opinion.7 Central to this relationship is the effort 
by scientists and government entities to communicate with and educate the public 
regarding bioscience, aimed at improving “Public Understanding of Science”. 
Inherent in approach is the assumption that public resistance to new science is partially 
based on incomplete knowledge and thus can be mitigated with better information.8 
 One of these key points about which the scientists are directing their efforts 
to “better inform” the public is that of the naturalness of genome engineering. 
Accusations that genome engineering is unnatural and thus deplorable has been one of 
the most visible and widespread criticisms against the genetic modification of 
lifeforms. A prominent example of the naturalness argument being employed in 
                                                 
6 Paul Berg, David Baltimore, Sydney Brenner, Richard O. Roblin, and Maxine F. Singer, "Asilomar 
Conference on Recombinant DNA Molecules," Science 188, no. 4192 (1975), pp. 991-994. 
7 Priska Gisler and Monika Kurath, "Paradise lost? ‘Science’ and ‘the Public’ after Asilomar," Science, 
Technology, & Human Values 36, no. 2 (2011), pp. 213-243. 
8 Monika Kurath and Priska Gisler, "Informing, Involving or Engaging? Science Communication, in 




opposition to biotech can be found in the opinions of the US presidential committee 
on the ethics of human cloning authored during the latter Bush presidency; Christian 
minister and ethicist Leon Kass, who was an influential member of this committee 
and one of the most vocal, argued in his work the Wisdom of Repugnance that 
immediate negative response (“repugnance”) to the unnaturalness of biotechnology is 
indicative of a deeper “wrongness” of the technology and thus is a sound reason for 
opposition.9  Various surveys have also noticed the widespread presence and influence 
of concerns over unnaturalness in opinions against GMOs and other products of 
genetic engineering. A 2011 overview of surveys regarding attitudes of US citizens 
towards farm animal cloning found concerns of unnaturalness to be prominent among 
detractors of cloning, considering it to be more important than issues of safety.10 A 
2010 EU policy research report also features concerns of unnaturalness prominently 
as a metric of public resistance to animal cloning and genetically modified foodstuff.11 
Naturalness is indeed a oft discussed and highly influential topic when it comes to 
biotechnology. 
 The attitude of scientists towards naturalness is muted and more sceptical. A 
2015 survey of various categories of literature by the UK-based policy research group 
                                                 
9  Leon R. Kass, "The Wisdom of Repugnance: Why We Should Ban the Cloning of Humans," 
Valparaiso University Law Review 32 (1997), p.679. 
10 Kathleen R. Brooks and Jayson L. Lusk, "US Consumers Attitudes toward Farm Animal Cloning." 
Appetite 57, no. 2 (2011), pp. 483-492. 
11  George Gaskell, Sally Stares, Agnes Allansdottir, Nick Allum, and Paula Castro, Europeans and 
Biotechnology in 2010: Winds of change? A report to the European Commission’s Directorate-General for Research on 
the Eurobarometer 73.1 on Biotechnology, FP7 project ‘Sensitive Technologies and European Public Ethics’ (STEPE) 
(Luxembourg: Publications Office of the European Union, 2010). 
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Nuffield Council summarizes the ways naturalness has been mentioned and discussed 
in literature by scientists, the press, members of parliament, and NGO activists for a 
period of 20 years.12 In the report scientists stand out as the group where the survey 
found zero value-laden mentions of naturalness; the scientists instead preferred to 
stick to value-neutral treatment of naturalness (as a strictly technical term regarding 
the non-artificiality of certain objects and phenomena), and in some cases even argued 
that to assign inherent value to naturalness was a fallacy. Discussions on why such an 
assignment is a fallacy can be found in the 2017 NAS report Human Genome Editing 
that followed the 2015 International Summit.13 The report argues that there is no 
single “natural” human genome, and that the argument that certain genes should be 
elevated and protected because it is natural “devolves to the view that the human 
genome should be treated with a sense of humility, and that humanity should 
recognize the limits of wisdom and science”. Observing that naturalness of a gene is 
indicative of neither safety nor benefit, the NAS report concludes that to prefer natural 
genes over unnatural ones by reason of naturalness alone is unsound. Human Genome 
Editing proceeds to assert that the potential dangers of human intervention should be 
addressed with further research, not by forswearing intervention entirely.14 
                                                 
12  Nuffield Council on Bioethics, Ideas about Naturalness in Public and Political Debates about Science, 
Technology and Medicine (2015), http://nuffieldbioethics.org/project/naturalness (retrieved 2018-07-09). 
13 National Academy of Sciences, Human Genome Editing. 
14 ibid., pp. 124-125. 
10 
 
 While naturalness as an argumentative point has been articulated for millennia 
and critiqued for centuries,15 naturalness has not been particularly under study in the 
specific context of genome engineering, despite the widespread use of the concept in 
debates. One prominent and useful research was the aforementioned survey by the 
Nuffield Council, a UK-based policy research group regarding bioethics that seeks to 
“inform policy and public debate through timely consideration of the ethical questions 
raised by biological and medical research so that the benefits to society are realised in 
a way that is consistent with public values”.16 Their report (Un)natural: ideas about 
naturalness in public and political debates about science, technology and medicine details the 
findings of their wide-scope survey of the ways the tern “natural” and “unnatural” 
have been used in parliamentary debates, scientific research, media reports, and NGO 
publications in the United Kingdom for a period of twenty years. 17  The report 
indirectly suggests a number of reasons that naturalness has not been subject of as 
much research as it could have been. One reason may be that beliefs about naturalness 
are deeply personal beliefs and are usually not subject to argumentation – one either 
believes it is good, or not.18 Another reason may be that, as a moral imperative that 
has been under scrutiny and criticism for several centuries (David Hume warned 
against the conflation of ‘is’ with ‘ought’, for instance), it has already been recognised 
                                                 
15Lorraine Daston and Fernando Vidal, eds., The Moral Authority of Nature (Chicago: University of 
Chicago Press, 2010). p.2 
16 Nuffield Council on Bioethics, “Our Aims and Values,” http://nuffieldbioethics.org/about/aims-
values (retrieved 2019-03-29).  
17 Nuffield Council on Bioethics, Ideas about Naturalness. 
18 ibid, p.17. 
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that distinguishing between natural and unnatural, and assigning positive or negative 
value to the categories, are not simple and the distinctions are for the most part unclear 
or not useful. Those familiar with the body of critique may even dismiss arguments 
based on naturalness out of hand; for instance, bioethicist John Harris is quoted as 
arguing the following: 
“… The argument from what is or is not natural need not detain us long. Since the 
whole practice of medicine is unnatural (people naturally fall ill and die prematurely), if 
we were to accept an ethic which required us not to interfere with what was natural 
there would be little for medical practitioners and medical scientists to do.”1920  
The problems associated with the authority of nature does not mean that naturalness 
is not a suitable topic of research, however. In their edited work Moral authority of nature, 
historians of science Lorraine Daston and Fernando Vidal proposed a study not of 
the legitimacy of the authority of nature but rather of its jurisdictions and workings; 
research on how naturalness is invoked by participants of debates, how strong an 
influence nature wields in a particular context, and what other kinds authority 
naturalness is associated with.21 Various chapters of the book deal with how the moral 
authority of nature is invoked in association with, or even in service to, other 
authorities and imperatives that the speaker has in mind. This paper is a case study in 
                                                 
19 John Harris and Søren Holm, "The Future of Human Reproduction: Ethics, Choice, and Regulation," 
(Oxford: Oxford University Press, 1998). Recited from ibid. 
20 This dismissal is similar to that found in the NAS report Human Genome Editing regarding the folly of 
forgoing all intervention. National Academy of Sciences, Human Genome Editing. 
21 Lorraine Daston and Fernando Vidal, op. cit., pp. 2-5. 
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this vein, focusing on the arguments set forth by Korean scientists at a “roundtable”, 
attempting to contextualize and provide a possible explanation to the particular ways 
the scientists invoke naturalness. 
 This “roundtable” is the 112th Roundtable on “Suggestions regarding the 
Realization of Gene Therapy in the CRISPR Era” held in the summer of 2017, focused 
on the current state of Korean CRISPR research in relation to therapeutic purposes 
and a brief comparison between international regulatory regimes.22 This event was a 
hybrid of panel discussion and press conference organized by the Korean Academy 
of Science and Technology (KAST), an originally independent but currently legally 
empowered body of esteemed Korean scholars in various scientific and technological 
fields that aims to promote the common interest of the sciences in Korea. The official 
aim of KAST is to “promote the basic sciences, and contribute to the advance of 
science and technology by recognizing and commending prominent scientists, and 
providing advice to the state”. 23  A notable case of KAST intervening in affairs 
regarding public understanding of science is its 2012 defence of the theory of 
evolution being taught in school textbooks, where the organization moved decisively 
to uphold the authority of the scientific community and the importance of proper 
                                                 
22 Korean Academy of Science and Technology, “112th KAST Roundtable Discussions: Directions for 
Legal and Regulatory Change Aimed at the Introduction and Utilization of Genome Editing 
Technology”, 2017. 08. 03. 
23 Quoted and translated from the original Korean. “기초과학연구의 진흥기반을 조성하고, 
우수한 과학기술인을 발굴, 활용함으로써 정책자문을 통해 과학기술 발전에 기여함을 
목적으로 설립되었으며…”  
Korean Academy of Science and Technology, “Purpose,” https://kast.or.kr/kr/kast/purpose.php 
(retrieved 2019-03-24), translated from the Korean original. 
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(orthodox) scientific knowledge in education.24 While the Roundtable was primarily a 
meeting between scientists and a small number of media representatives that were 
invited to promote the arguments of the scientists, it provides a valuable window from 
which to observe the opinions of Bioscience researchers in Korea about the current 
state of affairs, especially in regards to the Korean Bioethics and Safety Act in effect. 
KAST would later publish a policy advice pamphlet closely connected to this 
roundtable titled Biomedical sciences and human rights; this document is also under study 
in this paper.25 
 The topic of this paper pertains to the individual arguments employed by the 
scientists speaking at the roundtable in support of their overall position; in particular, 
this paper looks closely at the arguments which invoke naturalness or are referring to 
other arguments that invoked naturalness. This paper takes the position taken in Moral 
Authority of Nature that the authority of nature is seldom invoked alone, and seeks to 
connect these arguments based on naturalness to the rest of their arguments, aiming 
to construct a narrative that explains the way the scientists invoked nature. In doing 
so this paper seeks to provide a potential explanation as to what imperatives are 
driving the scientists to take their respective positions at the roundtable. 
 
                                                 
24  Kyoutae Kim, “Evolution of Archaeopteryx and Horses to Remain in Textbooks(시조새-말 
진화과정, 교과서 삭제 안될 듯)”, Dong-a Ilbo, 2012. 06. 25, p.A12.  
http://news.donga.com/3/all/20120625/47262715/1  
25 Korean Academy of Science and Technology, Medical-Life-Sciences and Human Rights (의생명과학과 
인권) (Seoul: Korean Academy of Science and Technology, 2018). 
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2. About the Invocation and Abjuration of Naturalness 
2.1. Existing literature on the relationship between bioscience and the public 
The Biotech industry has been an integral part of genome engineering research from 
its rise, and consequently a significant portion of prior research has scrutinised this 
context of commercialization of science. Much of this body of literature studies 
attempts by the aforementioned business interests to privatize bioscience “assets” 
such as isolated human genes of medical relevance, engineered lifeforms, or databases 
of gene distribution. Subsequent counter-efforts by numerous parties, mostly NGOs, 
to secure a more equal and just access to this “scientific commons” are studied as well. 
Myles W. Jackson’s work on the commercialization of the CCR5 gene identification,26 
Daniel J. Kevles’ work on Oncomouse and the origin of the current patent-based 
Intellectual Property regime regarding biological “inventions”, 27  Luigi Palombi’s 
critique of the effects of the patent regime that allowed privatization of isolated but 
naturally occurring genes,28 and Doogab Yi’s work on private business ventures arising 
out of publicly funded research and the policy-informed legal ideas that shaped the 
birth of the Biotech industry are some notable examples.29 These works detail the 
process through which a strong political impetus, arising from the American economic 
                                                 
26 Myles W. Jackson, "How Gene Patents are Challenging Intellectual Property Law: The History of 
the CCR5 Gene Patent," Perspectives on Science 23, no. 1 (2015), pp. 80-105. 
27 Daniel J. Kevles, "Of Mice & Money: The Story of the World's First Animal Patent," Daedalus 131, 
no. 2 (2002), pp. 78-88. 
28  Luigi Palombi, Gene Cartels: Biotech Patents in the Age of Free Trade (Cheltenham: Edward Elgar 
Publishing, 2009). 
29 Doogab Yi, "Who Owns What? Private Ownership and the Public Interest in Recombinant DNA 
Technology in the 1970s," Isis 102, no. 3 (2011), pp. 446-474. 
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landscape of the 1970s that called for scientific funding to be justified through tangible, 
accessible results, lead to widespread privatization of scientific knowledge in the 
United States. This in turn would lead to shifts in the way scientific research was 
framed and conducted; most of the research cited above has been critical of this shift, 
claiming that privatization leads to “shoddy science” as claimed by Jackson, or 
scientific-industrial monopolies as described by Palombi.  
 The relationship between the scientific community and the public, in particular 
those dealing with the epistemological authority wielded by scientists and the influence 
afforded by this authority over ordinary citizens, has long been a subject of intensive 
study. This is especially so in the United Kingdom where the 1985 Royal Society report 
on the subject, the Bodmer report, spurred the government into action to improve 
the “scientific literacy” of British citizens. This in turn lead to the formation of Public 
Understanding of Science (PUS) as a scholarly field.30 The 2000 House of Lords report 
Science and Society,31 suggested that despite educational efforts by the PUS programme, 
the measured values of scientific literacy among the British public had remained 
constant throughout the activities of the Committee on Public Understanding of 
Science. This failure to cause measurable change prompted scholars to re-evaluate the 
situation.32 This in turn led to the reconsideration, and eventual discrediting, of the 
                                                 
30 The Royal Society, The Public Understanding of Science (London: The Royal Society, 1985); Walter Fred 
Bodmer, The Public Understanding of Science (London: Birkbeck College, 1986). 
31 House of Lords Select Committee on Science and Technology, Science and Society, Third Report of 
the Session 
1999–2000 (London: HM Stationery Office, 2000). 
32 Steve Miller, "Public Understanding of Science at the Crossroads," Public Understanding of Science 10, 
no. 1 (2001), pp. 115-120. 
16 
 
theory that lack of scientific knowledge caused lack of enthusiasm for science, the so-
called deficit model.33 Science studies scholar Brian Wynne argued that the deficit 
model failed to account for the context of each citizen in their forming opinions 
regarding science, namely the level of involvement and knowledge of the political and 
social structure surrounding science and its governance. This context materializes as 
trust, which effects how much of and in what ways laypersons would “uptake (accept 
and adopt)” scientific explanations, and locality, which determines the compatibility of 
expert knowledge to the local context and thus affects the knowledge’s practical utility 
and social legitimacy. Failure to take this into account is evidence of the continued 
assumption on part of the scientists of the objectivity and unparalleled epistemological 
supremacy of science, argues Wynne; the scientists are mis-framing the 
misunderstanding of the locals.34 
 Susan Wright’s work Molecular Politics presents a detailed study into the social 
processes through which biosafety and bioethics governance was developed and 
practiced in the United States and the United Kingdom. Wright observes the existence 
of a “received understanding” among the scientists regarding the circumstances of 
these events, which tends to portray the deregulation process being driven primarily 
by technical issues and resolved primarily by the scientists’ technical efforts. Wright 
                                                 
33 Patrick Sturgis and Nick Allum, “Science in Society: Re-evaluating the Deficit Model of Public 
Attitudes,” Public Understanding of Science 13, no. 1 (2004), pp. 55–74. doi:10.1177/0963662504042690. 
34 Brian Wynne, “Misunderstood Misunderstandings: Social Identities and Public Uptake of Science,” 
Alan Irwin and Brian Wynne, eds., Misunderstanding Science?: The Public Reconstruction of Science and Technology 
(Cambridge: Cambridge University Press, 2003), pp. 19-46. 
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contrasts this understanding with the results of her analysis, which show that the social 
dimensions of the decision process were a crucial factor in the dismissal of the risk 
factors originally raised in concern. Wright argues that the various restricted-access 
scientific conferences that produced the supporting evidence for the deregulatory 
moves had been political gatherings aimed at pre-empting further regulations being 
imposed. For instance, in the immediate aftermath of the Asilomar conference, a key 
safety concern was the capacity of genetically modified bacteria becoming virulent and 
causing epidemics. In light of public controversies already brewing and those 
potentially on the horizon, the scientists imposed a voluntary moratorium on research 
until relevant questions of laboratory containment of genetic materials could be 
answered. Wright demonstrates that the process through which this concerns were 
dismissed, which happened at a rapid pace in the space of about two years, was shaped 
by closed-access meetings between scientists that actively sought out issues of 
potential concern, energetically investigated relevant topics, and disseminated their 
findings in a way that would preclude the concerns. This way, scientists were able to 
pre-empt government control of the lab safety issue and maintain freedom of scientific 
inquiry in the wake of the controversies regarding containment of engineered bacteria, 
all the while “addressing” the calls for reflexivity at the same time.35  
 This misremembering and the aforementioned misunderstanding may be 
connected, as further studies into the way the legacy of Asilomar and the beginning 
                                                 
35 Susan Wright, Molecular politics: Developing American and British Regulatory Policy for Genetic Engineering, 
1972-1982 (Chicago: University of Chicago Press, 1994). 
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days of genetic engineering show. There exists a healthy body of literature that studies 
bioscience in its early formative days, centring on the debates surrounding 
Recombinant DNA technology and the rise of the Biotech industry that followed. The 
Asilomar Conference that convened to resolve the debates and provide science with 
a direction acceptable to the public has been heralded as a landmark decision by 
prominent scientists and has been a central topic of study to date.36 The study by 
science studies scholars Priska Gisler and Monika Kurath Paradise Lost analyse the 
post-Asilomar science-Public relationship and the legacy of the 1975 conference.37 
Investigating how the conference was remembered and how this memory shaped the 
PUS policy efforts that followed, Gisler and Kurath discovers that the Asilomar 
Conference was being upheld as the ideal “other” upon which to contrast the 
disappointing present at which point science and the Public are seen to be constantly 
at odds. The authors describe the entire PUS effort as formulating and solidifying a 
division – akin to the “boundary works” as described by Gieryn demarcating the 
boundary between science and non-science38 – between science and the Public by 
emphasizing the existence of a gap, either in understanding or opinion, that needs to 
be bridged. The persistence of this “gap” reasoning has been observed by Kurath and 
Gisler in multiple cases where “new” science was met with public opposition: for 
nuclear science, bioscience, and nanotechnology, scientists and the state both 
                                                 
36 Gisler and Kurath, "Paradise lost?” 
37 ibid. 
38 Thomas F. Gieryn, "Boundary-Work and the Demarcation of Science from Non-Science: Strains and 
Interests in Professional Ideologies of Scientists," American Sociological Review (1983), pp. 781-795. 
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attempted to mitigate public concerns with educational efforts, evincing the 
understanding on the part of scientists that public opposition stems primarily from 
relative ignorance.39 The authors argue that, while there has been changes to the deficit 
model over the years and recent efforts to depart from it,40 the understanding of the 
“gap” that underlies the model has not been discarded. 
 In regard to the relationship between Korean bioscientists and the Korean 
public, much emphasis has been placed on ensuring the ethical behaviour of 
researchers in regard to the human rights of their test subjects and patients. That is 
the stated aim of the Korean Bioethics and Safety Act,41 and is understood as the 
central point of Korean bioscience regulation by jurisprudence scholars as well, since 
the 2012 revision that removed the other stated goals of the law and left only the 
protection of “human dignity and values” in Article 1. 42 This particular focus of 
Korean law can be associated with the aftermath of stem cell researcher Hwang Woo-
Suk’s rise and downfall, as this case involved numerous breaches of human rights of 
                                                 
39 Kurath and Gisler, "Informing, Involving or Engaging?" 
40 ibid. 
41  “Article 1 (Purpose): The purpose of this Act is to ensure bioethics and biosafety, thereby 
contributing to promoting citizens' health and improving their quality of life by preventing the violation of 
human dignity and values or the infliction of harm on human body in the course of researching on human 
beings and human materials or of handling embryos, genes, etc.” Emphasis added. Bioethics and Safety 
Act. Korean National Assembly Act, 2017 (Republic of Korea), no. 14839. Retrieved from the website 
of the National Law Information Centre.  
42 Hong Suck Cho, “The System, Contents, and Problems on new Bioethics and Safety Act,” Public Law 
Journal 13, no. 4 (2012), pp. 251-268. 
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patients who provided Hwang with genetic material (eggs) and were awaiting stem cell 
treatment that never materialized.43  
 An important and intriguing trait of the Hwang affair was that during the 
heyday of Hwang’s popularity, and to a lesser extent even after the fraudulent nature 
of his research was revealed, Hwang and also later bioscientists enjoyed immense 
support from the state and the public. This popular support has been a topic of intense 
study by researchers. Sociologist Kim Jongyoung writes that this fervent support for 
Hwang especially after Hwang’s downfall is linked to a widespread culture of mistrust 
of authority among Koreans in tandem with a strong nationalist, statist-patriotic value 
system linked with strong scientism that exhorted Hwang as a hero of the nation. As 
both the scientists themselves and the press reporting on them dipped into the well 
of nationalistic scientism for support, a strong narrative of heroic effort developed 
around Hwang’s lab, which achievements brought the state great honour, and will 
bring the people immense health benefits and wealth some point in the future. Hwang 
doing everything in his power to serve the public and the state with science. In this 
narrative, the way Hwang’s colleagues, and the state turned against Hwang as evidence 
emerged of his unethical conduct can be understood betrayal of a great man “after 
everything he has done for them”. This shared nationalist-statist ethos, narrative of a 
                                                 




scientist hero, and the subsequent sense of betrayal, Kim Jongyoung writes, are among 
the key factors behind the fervent Hwang support.44 
 The nationalist-statist arguments analysed by Kim Jongyoung is not limited to 
Hwang but seem to be common among later Korean bioscientists as well; the 
aforementioned connections of Korean research to international status and economic 
well-being of Korea as a country works in tandem with the more individualist 
arguments of biopolitics as described by Nikolas Rose.45 According to an analysis by 
bioethicist Jun Bang-Ook, rhetoric of patriotism, economic development, and an 
exaltation of the “heroic” efforts of scientists for the betterment of public health serve 
as powerful arguments for support of bioscience in Korea.46 Jun argues that such 
invocations of ethos and pathos are aimed at directing public gaze away from the 
concerns of the bioethicists, such as the ethical conduct of researchers and the ethical 
implications of the proposed technology. He blames the press of failing to separate 
these “emotional” arguments from ethical arguments, thus “exposing the public to 
the persuasive strategies of the scientists”. 
 While similar arguments are in use by the scientists at the 112nd Roundtable 
Discussions as well, and thus Jun’s analysis of scientist rhetoric still applies, the 
presence of naturalness-based arguments in the scientists’ position escapes Jun’s 
                                                 
44 Jongyoung Kim, “Making Sense of Fervent Hwang Woo Suk Supporters – Culture of Conspiracy 
and the Politics of Accusation,” Korean Journal of Sociology 41, no. 6 (2007), pp. 75-111. 
45 Nikolas Rose, "The Politics of Life Itself," Theory, Culture & Society 18, no. 6 (2001), pp. 1-30. 
46 Bang-Ook Jun, “Human Embryo Cloners’ Rhetorical Strategies in Korean Media Reporting,” Journal 
of the Korean Bioethics Association 6, no. 1 (2005), pp. 109-122. 
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analysis and deserves study. In particular where Jun argues that scientists use strategies 
of rhetoric to avoid handling ethical concerns, the scientists at the Roundtable instead 
seemed eager to claim that they too were concerned with the ethical issues, and their 
naturalness-based arguments can be understood as being their attempts at directly 
addressing some of those issues. After analysis of those arguments I believe that, while 
the argumentative positions of scientists may show little to no change, their approach 
to these concerns of outside parties may have changed. 
 
2.2. A Brief History of Naturalness as a Source of Moral Authority 
Naturalness, and its corollary unnaturalness, are states of being invoked by persons 
participating in debates regarding novel fields of science and technology, including but 
not limited to gene therapy. This is often done in a comparative, evaluative way, with 
“naturalness” being the presumed desirable state and everything “unnatural” being 
criticized, shunned, and warned against. This “value-laden” character of invocations 
of naturalness make them powerful points of argument in the relevant debates. While 
the invocations of naturalness often accompany more technical, more specific 
arguments regarding the focus of controversy, such as arguments on the safety (or 
lack thereof) of particular gene therapy methods,47 the naturalness itself appears on its 
                                                 
47 Hoongi Kim, The Rights to Know and Choose in the Age of Bioengineering Consumption (생명공학 소비시대 
알 권리 선택할 권리) (Seoul: EASTASIA, 2013). 
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own without qualifications, and the inherent value is unexplained, presumably because 
it is supposed to be self-evident.48 
 When considering nature as a moral authority, it is important to keep in mind 
its protean character, how it has embodied diverging values throughout history. From 
divinely ordained hierarchy to unadulterated purity that serves as a modern aesthetic 
norm, “naturalness” meant many different things at different times. Nature and its 
dictates have hardly been monolithic, and what a particular invocation of naturalness, 
especially the oft-damning categorization of “unnatural”, actually means in a given 
context varies heavily. The chapters of Moral Authority of Nature abound with examples 
of these various meanings of naturalness. Take for instance the invocations of nature 
in context of human sexuality. The allegories depicted in chapter 2 equate is fully with 
ought and the natural order refers to things as they are, i.e. as they were created. While 
creatures of God may deviate from the norm, they are still following their multiple, 
sometimes contradictory natures, and Lady Nature does not intervene. This contrasts 
with the autonomous nature as described in Onanism, where nature has given Man 
“natural urges” to procreate and severely punishes those who artificially go over the 
limits of the natural urges.49 The precise intent of any given invocation of naturalness 
is also somewhat dependent on who is making the invocation, and thus a study of the 
                                                 
48 Nuffield Council on Bioethics, Ideas about Naturalness. p.33. 
49 Katharine Park, “Nature in Person: Medieval and Renaissance Allegories and Emblems,” Lorraine 
Daston and Fernando Vidal, eds., The Moral Authority of Nature, pp. 50-73; Fernando Vidal, “Onanism, 




history of naturalness as an argumentative concept includes a study of those who 
sought to speak on behalf of nature, the theologians, the scientists, the historians 
drawing out grand narratives. 
 Naturalness or the concept of the natural state of things has a long history of 
being invoked as a moral authority in history, ranging from medieval discussions of 
“Lady Nature” dressed in majestic robes as caretaker and arbiter of divine order to 
modern characterisation of natural wilderness as an undisturbed, pristine reservoir of 
vigour and spiritual healing. Invoked primarily through the negative – condemnations 
of things unnatural rather than exhortations of things natural – the moral authority of 
nature has held a continuous hold on societal norms, compelling human society to 
deem what is as what ought to be, although the actual amount of influence has waxed and 
waned depending on the time period, along with the themes generally associated with 
invocations of nature. Moral Authority of Nature serves as an excellent introduction to 
the varied ways nature has been invoked and the evolution of the ways nature was 
understood and obeyed, or defied.50 
 The beginnings of nature as a distinctly moral authority dictating right and 
wrong can be traced to the medieval age, where nature was considered a divine 
creation and thus an embodiment of divine will inherent within the design. Thus, 
nature (usually personified as a female character of regal bearing) became a vicar of 




sorts to the authority of God, teachings beings to be as they were designated to be.51 
This primarily came to be invoked in arguments that condemned certain types of 
“abnormal” behaviour, especially non-standard sexual behaviours, which were 
announced to be crimes contra naturam, against nature. Although the authority of nature 
was rather limited in actual court proceedings – especially considering that in this 
mode nature had authority only in association to God, and thus nature stood in for 
and could always be supplanted by divine authority – it nevertheless formed an 
important part of the string of authorities that state actors could cite as justification 
for the use of its most extreme form of punishment, death. However, as jurisprudence 
became more professionalized and the Western legal tradition became more text-
based, the vague, multifaceted character of nature as a moral source became 
problematic, and arguments based on nature slowly but surely died out from courts 
of law.52 
 This would change drastically in the age of Enlightenment when Nature, now 
fully as an abstract entity that embodied all that was natural as a whole, came to be 
considered the most important authority on human values and the source of all moral 
thinking. Where formally “her” authority derived from and could be entirely replaced 
by that of God, Nature that appears in Enlightenment moral debates is more direct, 
more authoritative. Nature is armed with punitive powers of her own such as diseases, 
                                                 
51 Joan Cadden, “Trouble in Earthly Paradise: The Regime of Nature in Late Medieval Christian 
Culture,” The Moral Authority of Nature, pp. 207-231. 
52 Helmut Puff, “Nature on Trial: Acts ‘Against Nature’ in the Law Courts of Early Modern Germany 
and Switzerland,” The Moral Authority of Nature, pp. 232-253. 
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and actively visits harm and malady to those who trespass on her dictates. Nature was 
additionally endowed with new traits, such as objectivity and universality, that 
enhanced her moral authority over human society. Men of culture and learning were 
to deduce moral laws from laws of nature, its “unique and true source”, and advise 
others accordingly. While still associated with divine will as her authority ultimately 
still derived from that of God, Nature nevertheless was fully capable of promulgating 
and enforcing its own dictates, further reinforcing the moral necessity of obeying it.53 
 The authority of nature is said to be derived from its capacity to grant means 
of categorizing things: categorizing animals into subcategories like humans, mammals, 
birds and reptiles; humans into sexes and age groups; sexual behaviours into 
reproductive and non-reproductive. Once successfully grounded in nature, such 
categories gained social, moral, and even ontological significance that granted the 
divisions an air of legitimacy and made the divisions more pronounced and permanent, 
although as historian Londa Schiebinger writes in her chapter, the divisions were not 
so distinct nor considered physiologically inherent before the changes of the 18th and 19th 
centuries. Where before there was assumed to be a general unity to all humans that 
allowed experimental findings in medicine to hold true for all humans, there came to 
be an increasing perception that differences, especially race, meant different medicinal 
requirements, as studies of these “natural categories” intensified. Whereas in the 18th 
century experimenters deemed medical experiments using negro slaves as being 
                                                 
53 Fernando Vidal, “Onanism, Enlightenment Medicine, and the Immanent Justice of Nature,” The 
Moral Authority of Nature, pp. 254-281. 
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medically relevant for Europeans, especially if their non-natural conditions, such as 
level of physical labour, were similar, the question had to be deliberately confronted 
and received intense scrutiny in the late 18th and the 19th centuries as theories of 
scientific racism developed. 54  Nature’s authority not only established differences 
between categories but also similarities within categories; humans were to have 
“human nature” or humanness, men and women to have male and female 
characteristics, the races their each individual traits that were natural to them. To 
deviate from what these “natures” dictated was abnormal, dangerous, wrong. 
 This came to an abrupt shift in direction in the aftermath of World War II as 
Western civilization realized the extent to which innumerable horrors were committed 
in the name of race, the most politically pronounced of all natural divisions. In 
response, the 1950 UNESCO Statement on Race declared that race for all intents and 
purposes had zero scientific (and therefore, natural) basis, and was to be discarded as 
a scientific criterion. While this was obviously intended to undo the wrongs committed 
by human society in the name of nature and prevent future reoccurrences, this served 
as its own political influence that shaped human society in the name of nature in much 
the same way as did notions of race did in the late 19th century. In an ironic twist, in 
the two decades following the UNESCO Statement any finding of distinctions within 
the human species was considered unnatural and condemned as imagined spectres and 
remnants of a discredited view of human nature. This could have served as the political 
                                                 
54 Londa Schiebinger, “Human Experimentation in the Eighteenth Century,” The Moral Authority of 
Nature, pp. 384-408. 
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backdrop to the relative lateness in acceptance of the idea that there were various 
hominid species in contemporaneous existence in the course of human evolution. The 
same political-naturalist impetus could be argued to be behind the constant distinction 
of the modern human species from those earlier hominids, so that the “essential unity” 
of the human species is unmarred.55 There may be many hominids, but there was and 
is only one human species. 
 Nature when invoked as a moral authority today in genome engineering 
debates still maintains many of the characteristics such invocations shared in the age 
of Enlightenment, where nature is seen to be universal, and capable of directly 
punishing those who disobey her dictates. The categorization unnatural still holds 
strong connotations of unsafe and unsound, and modern arguments are often based on 
the dual meaning. However, as the Nuffield Council study (2015) suggests and the 
NAS report Human Genome Editing exemplifies, scientists are often dismissive of 
invocations of naturalness and warn against confusing the natural with safety or 
benefit.56 Similar dismissal of the sole use of naturalness can be found in criticisms of 
the Doctrine of Substantial Equivalence, a mainstay of current regulatory regimes of 
genetically engineered foods and drugs. Substantial Equivalence compares the 
chemical and physical characteristics between novel materials under scrutiny and a 
comparable sample found in nature; if the similarities are considered significant 
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Acheulean, and the UNESCO Response to Auschwitz,” The Moral Authority of Nature, pp. 466-490. 




enough (“substantially equivalent”) then the dangers associated with the novel 
material is assumed to be the same as the one found in nature and thus deemed 
“unproblematic”, or more precisely, no more problematic than nature. Criticism of 
this concept often involve arguments that ending the investigation at the 
demonstration of “equivalence” rests on the untested assumption that the natural is 
tolerably safe.57  
 
3. Naturalness and CRISPR: A Collection of Arguments 
The advent of genetic manipulation technology with the capacity to limit edits to 
highly specific sites on the genome, called “site-directed nucleases”58 or “genome 
editing” 59  by some, improved the accuracy and precision of genetic engineering 
sufficiently for a serious foray into its application to the human genome, the 
endeavour of human genetic therapy. By editing the genetic code of human beings, 
either in the foetus or in the developed human being, medical practitioners would be 
able to prevent the expression of deleterious hereditary traits, such as those serious 
enough to be seen as cause for genetic reproductive counselling. Even conditions not 
                                                 
57 Hoongi Kim, The Right to Know and Right to Choose. 
58 Nancy Podevin, Howard V. Davies, Frank Hartung, Fabien Nogue, and Josep M. Casacuberta, "Site-
Directed Nucleases: A Paradigm Shift in Predictable, Knowledge-Based Plant Breeding," Trends in 
Biotechnology 31, no. 6 (2013), pp. 375-383. 
59 Kim Jeong Hun, presentation at the 112th KAST Roundtable Discussions (2017). 
Origin of the term is a terminology box in a ZFN article by Urnov et al., in Box 1, where the authors 
explain that they wanted to distinguish their work from previous research named ‘gene targeting’. 
Fyodor D. Urnov, Edward J. Rebar, Michael C. Holmes, H. Steve Zhang, and Philip D. Gregory, 




directly tied to any specific gene are within the sphere of conditions that genetic 
therapy could potentially treat, as human metabolisms that enable those conditions 
could be changed to no longer facilitate the diseases. This is the case with the case of 
the therapy proposal by Kim Jeong Hun as showcased in our study. Kim seeks to treat 
Angiogenesis-Related Blindness, a family of eye conditions that share a common 
pathology of involving abnormal formation of superfluous blood vessels 
(angiogenesis) in the retina, by removing or disabling a gene associated with 
angiogenesis using CRISPR-Cas9. He aims to do this by delivering properly targeted 
CRISPR into the eye with very short-term vectors that will not survive long enough 
to escape the eye, thus containing the gene edit to the relevant organ. 
 CRISPR-Cas9 (hereafter simply referred to as CRISPR) is the latest in the 
series of the targeted genome editing tools, which includes earlier developments such 
as ZFN (Zinc-Finger Nucleases). While all genome editing tools share specifiability, 
i.e. the ability of the user to designate a specific target for the tool to work on, CRISPR 
is unique in that its target is selected by a sample DNA sequence that is directly 
compared to the target; if the sequences match, CRISPR cleaves the target. Whereas 
other side-directed nucleases involve formulating a custom-built nuclease for each 
different target, CRISPR requires merely swapping out the sample sequence with a 
new one to facilitate re-targeting. This simplicity of use is what led to the immense 
interest shortly after its discovery. 
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 With the promise of new therapies in hand, scientists began to argue against 
the numerous regulations in place that prevented or restricted genetic engineering of 
humans, either its research or application. In the United States these protests were met 
with favourable responses from government-related entities, with the US National 
Academies of Science, Engineering, and Medicine releasing the report Human Genome 
Editing: science, ethics, and governance in 2017 that conditionally allowed (“yellow-lit”) 
genetic engineering of the human germ-line that previously were restricted. 
Specifically, while the report reaffirmed the restriction on creating genetically 
engineered embryos for the purpose of creating an engineered human being, it argued 
that research involving embryos and other germline cells for the purposes of research 
could and should be allowed, in order for science to learn more, to promote 
developments elsewhere in the field.60 
 These new advances were met with resistance from those unfavourable to the 
expansion of genetic engineering, utilizing arguments both old and new. The 
aforementioned NAS report cites arguments such as those based on the imperfect 
safety record of genetic engineering thus far, the potential long-term effects of genetic 
changes that linger across generations (for germline edits), and the numerous 
questions of social justice that genetic therapy raises, ranging from broad questions on 
the righteousness of dividing human genetic traits into pathogenic and non-
pathogenic categories, to acute questions regarding the human dignity of the disabled 
                                                 
60 Prashant Nair, "QnAs with Alta Charo and George Church," Proceedings of the National Academy of 
Sciences 114, no. 23 (2017), pp. 5769-5771. 
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and disadvantaged.61 A number of these arguments were reproduced at the KAST 
Roundtable by Kim Ok-Joo, as we shall see in detail below. These arguments 
questioned the wisdom, or the necessity, of altering the human genome, although 
some questioned the authority of scientists to act unilaterally upon the gene pool that 
is “the common interest of all humankind” and therefore subject to the collective will 
of the entire human race.62  
 Many of these arguments involve naturalness. Some of the arguments do so 
directly, pointing at the unnaturalness of interventive techniques themselves that are 
involved in gene therapy, such as the viral vectors that deliver nucleases to the human 
cell. Some do so indirectly, as in arguments regarding the selection of certain traits for 
therapeutic “correction”: as these traits exist naturally in human beings, they are part 
of the overall human genetic pool that defines the human condition, and some 
opponents argue that any attempts to separately categorize these traits constitute 
discrimination. 63 Furthermore, as scientists at the Roundtable and the authors of 
Human Genome Editing point out, the human genome changes all the time – there exist 
                                                 
61 These arguments are summarized in different sections spread across the NAS report. Notable 
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of Human Intervention in pages 124-130, and the whole of chapter 6 “Enhancement”. National Academy 
of Sciences, Human Genome Editing. 
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communities, and have been raised against technologies such as prenatal screening to search for genetic 
“defects”. The NAS report provides a short summary in pages 30-31 dealing with the UN Declaration 
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“natural” genetic changes that occur with or without human intervention. Arguments 
against genetic engineering therefore become arguments against artificial, or perhaps 
unnatural, changes in the genome; as such, all arguments against gene therapy 
specifically become arguments at least partially based on an objection against 
unnaturality.64  
 While naturalness may be invoked by arguments on both sides of the debate, 
not all naturalness arguments are the same. As analysed by previous research 
summarized in section 2, there are multiple types of meanings that can be assigned to 
naturalness.65 When Kim Jeong Hun speaks about the naturalness of his proposed in-
vivo genome editing, he is speaking of a different nature from that referenced by Kim 
Ok-Joo when she argues that there is no “normal” gene, only natural ones. 
Furthermore, as the various chapters of Nature as a Moral Authority illustrates, nature 
has a long history of being employed by various interests for widely differing goals, 
and the how and why of invocations of naturalness need investigation. As such, this 
study undertook an analysis of the various arguments wholly or partially based on 
naturalness employed at the Roundtable and beyond in related circumstances, in an 
effort to examine how the invocations were made, with what goal. This will allow us 
to construct a narrative that explains the set of arguments. 
                                                 
64 Kim Jeong Hun, Kim Yon Soo, and Kim Jin-Soo, at the KAST Roundtable. Specific quotations 
follow below. Similar arguments, regarding the variability of “natural” genes and follies of certain 
possible categorizations, can also be found in the NAS report, at pages 124-130 and 138-139. 




3.1. The naturalness of minimalist CRISPR interventions. 
Kim Jeong Hun, the presenter at the 112th KAST Roundtable Discussions, is an 
ophthalmologist.66 He stresses that he is a practicing doctor, not a researcher; he deals 
with actual patients who suffer from blindness-causing conditions for which there is 
no cure commercially available. Foremost of these, he explains, is Angiogenesis-
Related Blindness (ARB), which is a family of conditions that share a common 
pathology, that of abnormal angiogenesis (formation of new blood vessels) in the 
retina. The build-up of blood vessels progressively inhibits the function of sight cells 
until they cease to function, and the eye loses sight. For the blood vessels to form, a 
certain protein called Vascular Endothelial Growth Factor A (VEGF-A) must be 
present to act upon the cells of existing blood vessels. There exists a treatment that 
takes advantage of this common link, the cancer drug Bevacizumab (trade name 
Avastin) originally developed for colonary cancer that supresses VEGF-A. However, 
using Avastin to treat ARB has a serious drawback in that it requires monthly 
injections of the drug into the eye cavity in order for the medication to work. Worse, 
the drug may not work or stop working after a while, as warned by the US National 
Eye Institute.67 Kim Jeong Hun argues that there is a need for a permanent, curative 
                                                 
66  Kim Jeong Hun, MD, Ph.D. Fight against Angiogenesis-Related Blindness Laboratory, Seoul 
National University Department of Biomedical Sciences.  
http://biomed.snu.ac.kr/main/tmpl_eng/sub_main.php?m_cd=35&m_id=0201&sp=2&wr_id=65 
67 “condition may progress even with treatment.” National Eye Institute, “Facts about Age-related 
Macular Degeneration,” https://nei.nih.gov/health/maculardegen/armd_facts (retrieved 2019-04-01) 
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procedure, and his team, Fight against ARB (FARB), is dedicated to finding that cure. 
His latest work is centred around using CRISPR to knock out the gene that controls 
VEGF-A function, thus preventing it from causing further angiogenesis in the eye. It 
is probably because of this direct connection to both CRISPR and a tangible medical 
need that Kim Jeong Hun was chosen to be the first to speak at the Roundtable. 
 As part of his presentation, Kim Jeong Hun defended the “naturalness” of his 
proposed gene therapy in two ways, based on the utilization of inherent repair 
mechanisms of the cell, and the lack of involvement of foreign genetic material, 
respectively. The most prominent of these was based on the strategy for knocking out 
the gene in question – the team intended to simply cut off the gene with a pair of 
Cas9-induced double-strand breaks, and then let the genome repair mechanisms 
inherent in the cell take over. A double-strand break (DSB) describes the cleaving of 
both helixes of the DNA sequence at a particular location; this prevents the usual 
repair mechanism for DNA damage from kicking in because there is no intact strand 
left to base the reconstruction of the other strand upon. 
 There are two possible outcomes for a DSB. One possibility is that the cell 
will restore the genome by cloning the sequence in the other, possibly non-
pathological, copy of the genome stored within the nucleus (available in all sexually-
reproducing eukaryotic cells, including those of humans) through a process called 
homology directed repair. The other possibility is that the cell will simply join whatever 
two severed ends that can be found into one, a process called non-homologous end-
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joining. It is the latter which is the primary intended outcome for FARB; once the 
ends are joined the resulting sequence will simply not have the relevant gene, having 
been cropped out with CRISPR. 
 Since either of these processes are internal mechanisms of cell physiology for 
repairing DNA lesions, there is theoretically little intervention required to facilitate it, 
and despite present imperfections in practice, Kim Jeong Hun is confident that such 
technical challenges will be overcome in time; to quote, “as the technology develops 
and improves, off-target effects are inevitably reduced. Further research leading to 
betterment of technology will surely solve the off-target challenge in time, which is 
reason to push forward despite the current state of the art.”68 In any case, Kim Jeong 
Hun argues that, outside of the CRISPR-aided double-strand breaks, his method 
involves no phenomena that is not native to the human cell. For this reason, he 
described his intended cure as being “very natural” in its application, a form of 
“miniscule” therapy achieving almost entirely natural results with almost natural means. 
 The crux of Kim Jeong Hun’s “minimalist” naturalness argument is of course 
the fact that the phenomena he relies on to achieve his goals are inherent to the cell. In 
emphasizing this, he is arguing against criticisms raised against former techniques used 
                                                 
68  Translated by me from the original statement in Korean. “유전자 교정 기술이 개발되면 
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Jeong Hun, presentation at the KAST Roundtable. 
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in genetic engineering, such as those regarding recombinant DNA technology that 
used viral vectors to introduce foreign genetic sequences into the human genome: 
As you know, double-strand breaks occur constantly inside our bodies. Even though 
DNA strands regularly break, fortunately there exist internal repair mechanisms in 
the body that ceaselessly repair these damages. In that we’re causing DSBs where we 
want in order to achieve our desired effect, “gene correction” is not so different from 
existing methods, except that instead of introducing novel material into the genome to 
achieve novel results, we are utilizing phenomena inherent to the cell. That the third 
generation genome editing (CRISPR) has advantages in its ease of synthesis and the 
capacity to run multiple edits at once over the 1st and 2nd generation tools (TALEN 
and ZFN) is well known. I am sure many of you are aware of this through various 
means.69 
Kim follows this up later with a statement on the “dangers” of some techniques: 
Once a double-strand break occurs, there are largely three possible consequences. One is 
where the deleted portion is not restored [due to non-homologous end-joining], resulting 
in gene deletion. Another possibility is a miniscule change of one or a few [codons]. 
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일으킨 것을 통해서 내가 원하는 효과를 얻는다는 점에서 기존의 새로운 어떤 것을 도입해서 
새로운 현상을 일으키기 보다는 원래 우리 몸에 있던 현상을 우리가 원하는 대로 프로그램 
해서 적용한다는 것만 다르지, 기본적으로는 굉장히 효과적인 방법입니다. 실제로 1세대 
2세대 유전자 교정 방법에 비해서 3세대 유전자 교정 방법이 쉽게 만들 수 있고, 동시에 여러 
개를 같이 할 수 있다는 장점은 이미 잘 알려져 있습니다. 이 부분은 이미 여러 차례 여러 자리 
여러 경로를 통해서 들어서 여러분이 이미 알고 있을 거라고 생각합니다.” Kim Jeong Hun, 
presentation at the KAST Roundtable. 
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These kinds of phenomena do not pose significant threats to the body. What we should 
be concerned about is when a foreign sequence is inserted in the place of the missing 
genes. This has been an issue with gene therapy: gene therapy [in the past] involved 
solving problems with existing genome by introducing foreign sequences to replace 
problematic functions. While our technique is not too different from previous gene 
therapy [in its effect], it is commonly misunderstood that we also insert foreign genes to 
the genome to achieve our therapeutic goals. My research, including my clinical trials is 
not about inserting foreign genetic material into the cell. We are researching options that 
are considered normal parts of the natural metabolism of the cell, such as gene deletion 
and substitution. In this regard I argue that we are technologically safer than previous 
genetic therapies. 70 
Why does Kim Jeong Hun emphasize the fact that his therapeutic strategy relies 
almost completely on inherent mechanisms? Seeing as the doctor is intervening in a 
situation where the human body has failed to fix itself (leading to blindness), shouldn’t 
                                                 
70 Translated by me from original statement in Korean. “DSB가 일어났을 때, 그 다음에 일어나는 
현상은 크게 3가지로 생각해볼 수 있는데요, 한가지는 그냥 나선구조가 부서지고 나서 이 
부위가 잘려지면서 그냥 deletion 되서 없어지는 거구요. 한가지는 한가지 정도의 아미노산 
바뀌는 정도의 변화. 사실 이런 정도는 전혀 위험성이 없습니다. 거기에 비해 우리가 
걱정해야 하는게 뭐냐면, 이런 deletion 을 만들어 놓고 그 안에 외부에서 무언가를 
집어넣는다면 당연히 걱정할 점이 있는거죠. 사실 이 부분은 유전자 치료가 가지고 있는 
문제입니다. 유전자 치료는 기존의 유전자의 문제를 해결하기 위해 외부의 유전자를 
집어넣어서 이 문제 기능을 대신하게 하는 방법입니다. 사실 생각해보면 그거랑 큰 차이는 
없는건데, 사실 우리는 어떤 오해를 하고있냐면, 유전자 교정이라 하면 유전자 치료와 같이 
새로운 유전자 하나 집어넣어서 그런가보다, 라고 하지만, 앞서 말씀드린 많은 연구들, 
그리고 제가 임상의사로서 제가 진행하고 있는 연구는 요 부위는 전혀 하고 있지 않습니다. 
저희는 정상적으로 일어나는 현상 중 하나라고 생각할 수 있는 deletion, substitution 같은 
굉장히 안전한 방향으로만 가고있고 김진수 교수님과 제가 하고 있는 연구는 요 방향만 하고 
있습니다. 그게 일단 기술적으로 안전, 이라는 것이 첫번째 우리가 생각해야 할 부분이구요.” 
Kim Jeong Hun, presentation at the KAST Roundtable. 
39 
 
he be emphasizing instead how the strategy does something the body can’t do on its 
own? Interrupting this function could lead to problems, especially in the long-term as 
the promised benefits of evolutionary fine-tuning, called “nature’s wisdom” by some, 
are unrealized; thus, it is imperative to obey its wisdom and not “unnaturally” “tamper” 
with its functions – hence his minimalist intervention being “safer” than more 
intrusive insertions of foreign materials.  
 However, if Kim Jeong Hun is conflating nature with safety, this raises a lot 
of questions. There’s of course the obvious matter of Kim Jeong Hun employing an 
argument that is usually cited in opposition to the epistemological authority of doctors, 
however there are other inconsistencies closer at hand. The report Human genome editing 
by the US National Academy of sciences, which Kim Jeong Hun cites in his 
presentation, describes in the section on “natural” human genome how this very logic 
is one of the foundational arguments underscoring the public opposition to gene 
therapy, and presents some counter-arguments based on dislodging the authority of 
naturalness.71 Kim Jin-Soo, a genome engineering scientist and one of Kim Jeong 
Hun’s research partners who provided the CRISPR know-how (he also is one of the 
speakers in the panel debate that followed Kim Jeong Hun’s presentation, more in 
section 3.3), quotes this very segment in adding that there is no single “natural” human 
                                                 
71 National Academy of Sciences, Human Genome Editing, pp. 124-125. 
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genome shared by all humans, and that concerns for preserving the natural state 
should not disparage efforts of the medical profession to cure and help people.72 
 Furthermore, Kim Jeong Hun himself contradicts the natural wisdom 
argument with the very mission of his research. Early on in his presentation the 
presenter had explained how there already exists a medication that treats 
Angiogenesis-Related Blindness: Avastin (Bevacizumab). Kim Jeong Hun noted that 
a major problem with Avastin was that it required monthly medication via intravitreal 
injection (i.e. a needle in the eye) and could stop working even if this schedule were to 
be maintained. One major advantage of gene therapy over this medication was that it 
could target the genes associated with VEGF-A and disable it, thus permanently 
dealing with the disease. However, this would be a more drastic intervention in terms 
of going against nature’s wisdom, as this therapy would render VEGF-A ineffectual 
in the eye permanently, unless another intervention of similar scope were to undo the 
change. This is unlike Avastin which is non-permanent and, more importantly to our 
investigation, is already proven to work. If one were to follow the invocation of nature 
as safety to its conclusion, one would have to foreswear gene therapy and continue to 
rely on monthly injections – contrary to what Kim Jeong Hun is seeking to achieve. 
If “minimal intervention” was to be a major selling point of the proposed gene therapy, 
Kim Jeong Hun is not presenting a very consistent case. 
                                                 




 In light of the apparent incompatibility between the conflation of nature with 
safety and his aim to use gene therapy to cure a disease which is already treatable, I 
questioned why Kim Jeong Hun brought up the inherence of the DSB repair 
mechanisms. There are probably many possible explanations, but the one that I deem 
most likely in light of the other arguments brought forth at the panel debate and Kim 
Jeong Hun’s close ties with Kim Jin-Soo, a specialist in the CRISPR field, is that this 
“minimalist” argument is not a general statement that compares his proposed 
treatment with Avastin. Instead, he was presenting a counter-argument to the notion 
that gene therapy in general is undesirable because genetic engineering is unnatural, 
using unnatural means to create unnatural beings. His argument is one in favour of 
CRISPR gene therapy in comparison to previous modes of genome engineering; it is 
aimed primarily at allaying the worries people have about the technology. 
 Why does this localized argument against particular naturalness-based 
opposition to gene therapy appear in Kim Jeong Hun’s presentation? Why is this being 
mentioned in front of an audience of mostly retired scientists of the Korean Academy 
of Science and Technology? That I argue is closely connected to the stated goal of 
both the presentation and the 112th Roundtable Discussions. As suggested by the title 
of Kim Jeong Hun’s presentation, “Proposal for the realization of clinical application 
of gene correction in the age of CRISPR: A toe in the door for clinical application of 
genome editing in the era of CRISPR”, the argument is part of a proposal on 
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persuading people to push for deregulation of CRISPR research.73 The argument is 
aimed first and foremost at the ultimate audience to whom scientists must “sell” their 
proposal, the public. 
 
3.2. No “dangerous” insertions: a non-transgenic argument 
As seen in the preceding section, Kim Jeong Hun eagerly advertises the inherence of the 
phenomena he utilizes to differentiate his technique with previous techniques, which 
according to his description involved insertion of foreign sequences. However, Kim 
Jeong Hun does not address in the presentation why he is asserting that insertions of 
foreign sequences are dangerous per se, nor does he advertise this difference in his 
publications where a deeper explanation may have been included if he had.  
 Digging for clues as to what danger he was referring to, one can after some 
searching find reference to the regulatory landscape (of the European Union, in fact) in 
one of the papers co-authored by Kim Jeong Hun’s collaborator Kim Jin-Soo.74 Highly 
efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins 
cites several reasons why insertion of foreign sequences is relatively “problematic”. 
The target genome may become contaminated with parts of the carrier genome that 
                                                 
73  Kim Jeong Hun’s presentation, KAST roundtable. “CRISPR 시대에 유전자교정 임상적용 
실현을 위한 제언: A toe in the door for the clinical application of genome editing in the era of 
CRISPR” 
74 Sojun Kim, Daesik Kim, Seung Woo Cho, Jungeun Kim, and Jin-Soo Kim, "Highly Efficient 
RNA-Guided Genome Editing in Human Cells via Delivery of Purified Cas9 Ribonucleoproteins," 
Genome research 24, no. 6 (2014), pp. 1012-1019. 
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was not part of the intended insertion. Insufficient specificity of target location 
identification may result in the insertion of foreign sequences in unintended locations 
(something called off-target indel; this is actually one of the central features in the 
Roundtable presentations, as we shall see below) which are more difficult to anticipate 
than errors on the target location. Foreign material may cause an immune response 
from the host and may linger for some time before they dissipate or are removed. 
 Interestingly, Highly efficient RNA-guided genome editing also cites a couple of 
European Union policy research papers that summarize how much of the existing 
regulatory oversight of genetic engineering rely on the “dangers” associated with these 
foreign material insertions, or “transgenesis” to use the legal term.75 These two papers, 
Engineering nucleases for gene targeting: safety and regulatory considerations (Pauwels et al.) and 
Site-directed nucleases: a paradigm shift in predictable, knowledge-based plant breeding (Podevin et 
al.), argue that, in light of the concern of government bodies with transgenesis, 
avoiding the category altogether by not involving foreign genes – “transgenes” – will 
save scientists considerable time and expense related to regulatory compliance. The 
method of doing so is through cisgenesis – utilization of genetic material native to the 
organism in question, perhaps the very same individual. Although not directly related, 
                                                 
75 The two articles referenced by Kim Jin-Soo’s paper deal primarily with the development of new 
commercial plant breeds, where the safety concern of the regulations is significantly lax compared to 
the oversight of gene therapy, as noticed by Pauwels on one of the two articles. 
Katia Pauwels, Nancy Podevin, Didier Breyer, Dana Carroll, and Philippe Herman, "Engineering 
Nucleases for Gene Targeting: Safety and Regulatory Considerations," New Biotechnology 31, no. 1 (2014), 
pp. 18-27. 
Nancy Podevin, Howard V. Davies, Frank Hartung, Fabien Nogue, and Josep M. Casacuberta, "Site-
Directed Nucleases: A Paradigm Shift in Predictable, Knowledge-Based Plant Breeding," Trends in 
Biotechnology 31, no. 6 (2013), pp. 375-383. 
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there is evidence of such an argument already working in the case of agribusiness 
concerns trying to circumvent USDA definitions of GMOs: Noting that the current 
definition is dependent on transgenes, the United States Department of Agriculture 
had told researchers some time ago that it would not regulate newly developed cisgenic 
products on the grounds that they are not transgenic.76 Could this legal context be the 
reason why Kim Jeong Hun differentiates between previous transgenetic techniques 
and his new, non-transgenic approach? I believe this is highly plausible, especially 
considering that he relied upon the non-transgenic argument for cisgenesis almost 
verbatim in his presentation as seen above. Later in his presentation while discussing 
the fine print of the Korean Bioethics and Safety Act, Kim Jeong Hun adds the 
following: 
It may be that I am misreading this law, but as I understand the Korean Bioethics and 
Safety Act requires all research on gene therapy that seeks to deliver hereditary 
substances or cells containing such substances into the body must meet one of the two 
criteria presented therein. Insertion of genetic material needs to meet only either criteria 
1 or 2. Our genome editing plan, despite being much safer than such insertions, must 
meet both criteria. If they demand that I justify my research on both grounds by the 
letter, I would need to stop my work immediately. As I mentioned previously before my 
description of CRISPR gene therapy, there already is a suppressor for VEGF-A. 
                                                 
76 Two Nature news articles by Emily Waltz illustrate the success of this argument in the United 
States succinctly.  
Emily Waltz, “Tiptoeing around Transgenics,” Nature Biotechnology 30, no. 3 (2012), pp. 215-217; 




This means I do not meet the criteria set forth by the law; the law prevents me from 
studying anything other than the already available method, VEGF-A suppression.77 
The two criteria that Kim Jeong Hun is referring to here are the two criteria defined 
in Article 47 Section 1 of the Korean Bioethics and Safety Act.78 While Kim Jeong 
Hun’s particular interpretation of the distinction between the two types of gene 
therapy (one that must meet both criteria and the other that only needs to meet one) 
may be questioned, what is more relevant to the question at hand is how he reacts to 
the distinction as he just defined it. He asserts that what distinguishes the two types is 
the transgenics criterion (“insertion of genetic material”) – and implies that it is being 
applied backwards, i.e. non-transgenic procedures are “much safer”. He does not go 
                                                 
77 Translated by me from original statement in Korean. “제가 이 법을 잘못 이해하고 있는 걸지는 
모르겠는데, 제가 이해하고 있기는 여기 보시면 유전 물질 유전 물질이 도입된 세포를 
인체로 전달하는 일련 행위는 1,2번 행위 중에 하나만 만족하면 된다입니다. 그래서 유전자 
치료, 외부 유전자를 넣어주는 건 1,2번 중 하나만 만족하면 되는 것 같은데요. 저희가 하는 
유전, 제놈 에디팅은, 오히려 유전자 넣어주는 거 보다 오히려 앞의 두 방향으로 나아간다면 
훨씬 안전한 방법인데도 이 두가지를 모두 만족할 때에만 할 수 있다고 합니다. 그럼 이 
두가지 모두를 만족하려면 저희는 안과는 이 연구를 멈춰야 합니다. 제가 앞서 말씀드릴 때 
유전자 교정을 말씀드리기 전에 눈에는 나쁜 혈관이 생기는 게 문제고 나쁜 혈관이 생기는 
걸 막으려고 VEGF 억제제가 만들어졌다고 말씀드렸잖아요. 여기 보면 현재 이용 가능한 
치료법이 있기 때문에 눈에서는 VEGF 억제제 이외에 유전자 교정법 연구를 하면 안됩니다.” 
Kim Jeong Hun, presentation at the KAST Roundtable. 
78 Article 47 (Gene Therapy) (1) Research on a gene therapy that falls into a series of procedures to alter genes in the 
body may be conducted in cases that meet both of the following conditions:  <Amended by Act, no. 13651, Dec. 29, 
2015> 
1. Research on a therapy for a hereditary disease, Acquired Immune Deficiency Syndrome (AIDS), or any 
other disease that threatens one's life or causes a severe disability; 
2. Research on a therapy where there is no applicable therapy at present or the effect of a gene therapy is expected 
to be significantly better than other therapies. 
(2) Research on a gene therapy that falls into a series of procedures to transfer hereditary substances or cells to which 
hereditary substances are introduced, to the body may be conducted only when falling under either paragraph (1) 1 or 2.  
<Newly Inserted by Act, no. 13651, Dec. 29, 2015> 
Bioethics and Safety Act. Korean National Assembly Act, no. 14839 (2017). Retrieved from the website 





deeper into why the procedures are safer, but it seems evident by this point that Kim 
Jeong Hun is indeed employing the non-transgenic argument to promote his research. 
 The inconsistency of using the non-transgenic argument to promote gene 
therapy is that many of the concerns that birthed and developed the transgenic 
criterion were based on circumstances other than manipulation of the human genome. 
This is obvious when one considers where all the transgenesis-related regulations are 
found: in GMO regulations. A major consideration behind the precautions around 
transgenesis is that it is considered to be riskier than more “traditional” methods of 
inducing beneficial mutations, or “mutagenesis” to use the technical term, such as 
selective breeding or exposing plant genes to ionizing radiation.79 As transgenesis 
imparts novel genes and therefore novel expressed traits to the target organism, and 
may result in a specimen that displays, unpredicted, unwanted and perhaps dangerous 
traits that would require its isolation, many government bodies thought it prudent to 
introduce specific controls for transgenic crop (and animal) development. One 
particular concern with the safety of old-school transgenesis is that while the sequence 
being introduced is under control, the insertion process itself is not, and the new 
sequence might land anywhere on the target genome, especially since being of foreign 
origin there is no specific place that the sequence belongs. In fact, another concern 
with transgenesis is that insertion usually involves extra bits of genetic material that 
                                                 
79 Didier Breyer, Philippe Herman, Annick Brandenburger, Godelieve Gheysen, Erik Remaut, Patrice 
Soumillion, Jan Van Doorsselaere et al., "Commentary: Genetic Modification through Oligonucleotide-
Mediated Mutagenesis. A GMO regulatory challenge?" Environmental Biosafety Research 8, no. 2 (2009), 
pp. 57-64; Podevin et al., op. cit. 
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are intended to allow the foreign sequence to successfully join with the target DNA 
despite the lack of a matching home, and these may not function as expected. Even 
contamination by sequences entirely outside the intended insertion package is possible, 
and is another problem that plagues the older method. 
 “Genome editing” refers to the new, site-specific methods of genome editing 
that do not rely on fortuitous insertion of genetic materials and instead cause 
mutations via double-strand breaks at precisely defined sites in the target genome, as 
explained regarding CRISPR in section 3.1. The term itself was devised by Urdnov et 
al., regarding zinc finger nucleases (ZFN), one of the earlier genome editing methods, 
to draw attention to the novel implications of the capability of these new techniques 
for site-directedness.80  
 The non-transgenic argument applies to products of the new “genome-editing” 
tools such as ZFN and CRISPR that do not involve insertion of genetic material to 
the target organism. As no new genetic material is introduced wholesale into the target 
genome, the range and scope of possible genetic changes fall within the scope of 
possibilities of the aforementioned “traditional” methods. The same is true of the 
process as well: as explained in the previous section, genome editing works by 
introducing a Double Strand Break at specific locations, which is also what happens 
with “natural” mutations or traditional means of mutagenesis such as radiation 
                                                 
80 Urnov et al., (2010), “Genome Editing with Engineered Zinc Finger Nucleases.” Box 1 explains the 
significance of the new term and why it isn’t called gene targeting instead. 
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bombardment. This is why the non-transgenic argument is associated with 
deregulation: there are no grounds for subjecting genome editing to “extra” oversight 
like that for transgenesis, as they are just like old methods, results-wise. The same old 
rules for traditional methods should suffice. 
 In contrast, there is no traditional method of gene therapy. There is no “baseline” 
set of laws that the Korean Bioethics and Safety Law should revert to in response to 
the non-transgenic argument, because there was no (openly practiced) genetic 
manipulation of human beings in the first place. Thus, any genetic therapy is novel and 
therefore potentially dangerous, no amount of non-transgenic arguments can lower 
the perceived risk. The only relevant questions are the most basic ones: just how safe 
is CRISPR gene therapy? Even though targeted mutagenesis has little chance of 
causing widely unexpected mutations in the target organism, isn’t any non-ordinary 
change potentially dangerous and entirely non-acceptable for in-vivo human gene 
therapy? 81  Of course, both Kim Jeong Hun’s presentation and Kim Jin-Soo’s 
discussion of the topic include arguments aimed at answering the relevant questions 
– for instance, Kim Jeong Hun’s mention of the occurrence of off-target indels in 
CRISPR-empowered genome editing and his efforts to reduce them, or Kim Jin-Soo’s 
                                                 
81 “For NBGT applications where the enrolment of the recipient organisms in such elaborate screening 
and selection programs is less feasible or even not acceptable (e.g. gene therapy), the identification and 
molecular characterization of intended and potential off-target cleavage sites remain important aspects 
for the assessment and anticipation of potential unintended and adverse effects.” Pauwels et al., (2014), 
“Engineering Nucleases for Gene Targeting: Safety and Regulatory Considerations,” p. 24.  
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answer to Kim Ok-Joo’s concerns regarding social justice – but the non-transgenic 
argument remains irrelevant. 
 Then why was the transgenic argument employed in the first place? It may be 
that Kim Jeong Hun, being an ophthalmologist, was unaware of the precise context 
of the non-transgenic argument and referenced it as a mistake, but seeing as he made 
almost the exact same presentation almost a year later at the Korean Federation of 
science and Technology Societies Annual Meeting, collaborating once again with Kim 
Jin-Soo, I see little reason to suspect that the presentation was poorly planned or 
inadequately researched. Kim Jin-Soo in particular is a veteran of promoting gene 
therapy in the media, having participated in the 2015 International Summit on Human 
Gene Editing, and would be well-versed in the intricacies of the non-transgenic 
argument and how it relates to various bodies of regulation on biotechnology. Kim 
Jeong Hun reports that he has coordinated with Kim Jin-Soo regarding the 
presentation’s contents and sometimes quotes Kim Jin-Soo directly;82 if there was 
something problematic about Kim Jeong Hun’s employment of the non-transgenetic 
argument, then Kim Jin-Soo would have probably advised his collaborator against it.  
 The explanation that I think fits best is that, once again, they are answering an 
argument about the unnaturalness of gene therapy, one that was not present at the 
roundtable itself but rather originates with the public. While the transgenics criterion 
                                                 
82 “When I first started work on genome editing with Kim Jin-Soo, I first asked him to confirm for me 
two things…” “Kim Jin-Soo constantly assured me of the safety of CRISPR…” “…I believe this 
explanation by Kim Jin-Soo illustrates the situation best…” Excerpts from Kim Jeong Hun’s 
presentation, KAST roundtable. 
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is arguably irrelevant to human genome editing, it nevertheless is a very high-profile 
topic, being at the heart of most currently active GMO regulatory schemes. It is 
transgenics that gives GMOs the moniker “frankenfoods”, and by disassociating their 
gene therapy with the controversy surrounding GMOs perhaps the two Kims sought 
to avoid a similar opposition regarding their gene therapy plans. As the two Kims 
describe it, there’s nothing eerily unnatural about gene therapy; it deals not with 
Frankenstein’s monsters but rather deals with utilizing natural phenomena to 
rearrange natural genes in novel ways. 
 
3.3. Human enhancement and the “natural” human gene pool 
Kim Jin-Soo is a scientist whose career straddles both the academia and the industry, 
having been a Samsung researcher before he opened his own company, Toolgen, 
which he continues to run to this day. Toolgen makes biomedical tools for use in both 
research and industrial applications, and digenome-seq, an in-vitro whole-genome 
sequencer for determining the off-target ratio in a Cas9-digested genome, 83  is 
Toolgen’s most prolific product. Digenome-seq is seen in use in Kim Jeong Hun’s 
research into using CRISPR to knock out the VEGF gene to determine the 
improvement in off-target indel minimalization, for instance. Kim Jin-Soo maintains 
his simultaneous position as head of Toolgen and as an academic at Seoul National 
                                                 
83 Daesik Kim, Sangsu Bae, Jeongbin Park, Eunji Kim, Seokjoong Kim, Hye Ryeong Yu, Jinha Hwang, 
Jong-Il Kim, and Jin-Soo Kim, "Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target 
effects in human cells," Nature Methods 12, no. 3 (2015), p. 237. 
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University. He is active in the media, being a vocal proponent of the entrepreneurial 
mindset among academics and the deregulation of gene therapy research. He is often 
found lamenting about how Korea is committing industrial self-harm by restricting 
research in his interviews.84 
 The way presenters, especially Kim Jin-Soo, invoke naturalness can be 
described as reactionary, as they are answering commonly raised arguments against 
genomic engineering in general. This aspect is most directly evident in the words being 
used to promote the proposed cure for ARB and responds to arguments raised against 
the promotion. As noted numerous times, Kim Jeong Hun’s description of his 
research project is keen to label his therapy as “genome correction”, as opposed to 
just “gene therapy”. One aspect of this distinction was its minimalist nature, as his 
CRISPR scissors will be able to achieve the therapeutic goal with only minimal 
interventions, utilizing natural phenomena inherent in the cell. Another aspect of this 
distinction was the technique’s non-transgenic, non-alien nature, introducing no 
foreign material into the genome and leaving no traces in the cell after the correction 
is complete. The last aspect of the distinction highlights the naturalness of the 
objective of the technique: the distinction between Gene Therapy and Genome 
                                                 
84 Tae-Il Kim, “Kim Jin-Soo ‘changing the world with gene therapy’,” Haemophilia Life(헤모필리아 
라이프), 2016. 02. 11. 
Hoe-Sup Won, “Director Kim Jin-Soo says ‘Korean Regulation Stifles Technological Advancement in 
the Midst of Genome Editing Patent Wars’,” Maeil Business, 2016. 05. 18. 
Seong-Ho Cho, “Chosun Monthly Interviews Kim Jin-Soo ‘Suspected of Patent Commandeering’,” 
Chosun Monthly, 2018. 09. 10. 
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correction is, according to Kim Jeong Hun, that correction only seeks to restore the 
“errors” in the patient genome into the “healthy” or “normal” state.85  
 This “restoration” distinction can be explained as follows. As described above 
in section 3.1, there are two possible results from the initial Double-Strand Break. One 
is non-homologous end joining (NHEJ), where the cut ends of the DNA strand are 
simply put back together. This can be utilized to delete a section of the genome by 
cutting at two points in such a way that NHEJ would put the two farther points 
together, instead of the actually cut points. Another is homology directed repair, where 
the repair mechanisms of the cell try to restore the lost gene by reconstructing a new 
sequence based on the other set of genes stored within the cell. As long as this other 
copy of the gene is not of the pathological form, the one that causes abnormally high 
rate of blood vessel formation through pathological activation of VEGF-A, the 
restoration of this gene would result in a successful cure of ARB. 
 The wording of the label “genome correction”, as explained by Kim Jin-Soo, 
refers to this “restoration of the non-pathological state” that is the intended goal of 
                                                 
85 Genome correction is my translation for the Korean term in use by the two Kims, 유전자 교정. 
The term for the most part is treated by the presenters, especially Kim Jeong Hun, as being a straight 
translation of Urdnov et al.’s “Genome Editing,” as can be seen in the way Kim Jeong Hun describes 
three generations of “gene correction” and how foreign research teams are going forward with its 
human applications. In light of the numerous differences in which the presenters use the term to 
distinguish their research from previous gene therapy proposals, however – especially the particularly 
normative argument studied in section 3.3. – I believe that the term should be considered distinct from 
the original as used by Urdnov et al., To this end I maintain the wording “correction” when referring 
to the arguments put forth by Kim Jeong Hun and Kim Jin-Soo. 
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FARB’s method.86 This “corrective” direction is what he considers to qualify the 
planned method as being truly “therapeutic”, as opposed to other possible forms of 
human genetic engineering which may instead lead to human enhancement, a particular 
topic of human genetic engineering that is a major focus of opposition to deregulation 
of gene therapy.87 To quote him, genome correction does not produce super-humans, 
it only produces normal ones.88 
 A significant portion of opposition to human genetic engineering, especially 
heritable edits to the germline, rests on the argument against human enhancement, 
which predicts that proliferation of genetic engineering of humans would lead to the 
technology being utilized to push individuals beyond the current range of human 
genetic expression, resulting in a hereditary group of “super-humans” that are 
advantaged in relation to the non-enhanced population.89 As gene therapy is expected 
to be expensive and limited to only a small portion of the human race, the group of 
people enhanced in such a way could not only introduce a new source of inequality 
but do so in a way that closely follows and exacerbates the current divisions of wealth 
                                                 
86  While Kim Jeong Hun never makes the normative distinction of “correction” explicit in his 
presentation, he does call his intended tactic “substitution”, which he mentions is safer and more 
“normal” compared to “insertion” of transgenesis. 
87  This topic was raised by another of the panel debaters, Medical Historian Dr Kim Ok-Joo. 
“Deregulation and proliferation of gene therapy could lead to changes in social opinions and regulatory 
impulses that would allow genetic engineering to change patient genomes beyond what can be 
understood as being therapeutic, into levels that could grant advantages to the patient.” 
88 “Those who had followed my research closely, those able to read into the details, would realize the 
truth of [what I am arguing right now] on their own. Human enhancement is made more difficult, not 
easier, by refocusing efforts on genome correction.” Emphasis is mine. Kim Jin-Soo’s panel discussion, 
KAST roundtable. 
89 Human Genome Editing. pp. 137-161. 
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and social class.90 Even though gene therapy may be introduced and initially utilized 
in ways that do not venture into enhancement, the resulting social “acclimatization” 
to human genetic engineering and maturation of the technology may eventually evolve 
society to the point where human enhancement occurs; this argument is called the 
“slippery slope” argument.91 
 Concerns of potential social justice issues are not limited to the slippery slope. 
In direct opposition to this “Restoring the Normal” argument, historian of medicine 
Kim Ok-Joo (the only non-scientist in the panel) in her panel discussion pointed out 
that the very concept of “normal” in regard to the human genome was problematic 
and was embroiled in a social justice debate of its own. The debate can be summarized 
into the assertion that there is no “ideal state” to which the “normal” or the “medically 
sound” can be boiled down into; instead, there is always a wide variety of genes found 
in the human gene pool, and they are all “natural”, “human” genes. The human 
genome runs a wide range of expressive traits, and the “benefits” and “disadvantages” 
of individual phenotypes are dependent on the particular context within which the 
trait is expressed. Furthermore, even considering this, some traits that are usually 
considered “unquestionably” disadvantageous can nevertheless be considered normal, 
even essential, for some individuals. For instance, for the inherently blind, their 
blindness may not be an immense disability but simply an everyday part of life – for 
                                                 
90 Dr Kim Ok-Joo’s discussion, KAST Roundtable. 
91 Human Genome Editing. pp. 128-130. 
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them, the sense of sight does not even exist.92 While this radically contingent nature 
of the question of normalcy is highlighted in the case of heritable genetic disabilities, 
it is not limited to such communities. The very attempt to define and use the term 
normal in regard to humans raises questions of who has the right to define it, and 
what happens to those who fall outside it.  
 Problems of the concept of the normal state become more acutely visible 
when one considers the legacy, both direct and indirect, of eugenics within discussions 
of genetic therapy. As Kevles (1995) points out in In the Name of Eugenics, “the 
definition of defect might become once again a hereditarian cloak for social 
prejudice.”93 The eugenic impulses to “improve” the human gene pool and remove 
“pathologic” genes and phenotypes from existence are still detectable in modern 
genetics, and it is because of this shadow that the modern world, or at least the United 
States where eugenics “was always associated with racism”, is as of yet still wary of 
human genome editing. This general aversion to genetic improvement and 
enhancement is also noted in the NAS report, which briefly discusses its history while 
noting that the same arguments were presented, discussed, and ultimately abandoned 
in regard to prenatal genetic screening. The report continues that genetic screening, 
while an ongoing source of tension within and around the disabilities community, did 
not lead to the numerous social problems that its widespread use was feared to herald; 
                                                 
92 This particular example is quoted directly from the 2017 NAS report. 
93 Daniel J. Kevles, In the Name of Eugenics: Genetics and the Uses of Human Heredity (Cambridge: Harvard 
University Press, 1995). 
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the report observes, for instance, that the time period in which the screening 
technology became more widely used was also the period in which public acceptance 
of disabilities increased markedly. However, in the end the NAS report concedes that 
the issue is very unlikely to become closed in the near future and will merit continuous 
deliberation. 94  As further developments in the field of genetic engineering ever 
increasingly empowers humankind’s ability to rewrite its own biological basis, the fear 
that a more terrible form of eugenics might be birthed from the ashes of the old one 
continues. 
 Kim Jin-Soo was also careful to note that continuous communication between 
the various parties was necessary, but interestingly enough, the participants in the 
conversation he was envisioning was not the scientists and the public but rather the 
scientists and the ethicists. Noting that the NAS report from which he was quoting 
liberally was written by a committee chaired by a professor of law and bioethics, Alta 
Charo, Kim Jin-Soo remarked “surely there are ethicists in Korea who can come up 
with a similar text” and promised that if any ethicists were just willing to come 
knocking on his door, he would be ready to explain to them everything they’d like to 
learn about genome correction.95 While he asserted this conversation will be two-way 
                                                 
94 Human Genome Editing. pp. 125-127. 
95 Translated from the original statement in Korean. “결국에는 이런 유전자가위 연구자들과 
생명윤리학자들 사이에 정보 공유와 소통이 정말 중요 하다는 것이죠. 그래서 저는 
생명윤리학자들이 기술에 대해 우려를 갖고 있고, 염려하시는 분이 있다면 언제든지 절 불러 
주시면, 제가 만사를 제치고 달려가서, 가서 정말 정확히 말씀드리고, 우려하시는 부분이 
어떤 것인지 밤을 세서라도 듣고 싶습니다. 어떤 부분은 기술적으로 해결할 수 있을 것이고, 
어떠한 우려는 그냥 기우일 수도 있는 것이고, 생각을 통해서 해결할 수도 있을 것이고, 서로 
소통한다면, 연구자들도 발전할 수 있을 것이고, 생명윤리학자들도 오히려 건설적으로 
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and that both parties will have something to learn from the other, the fact that he has 
already established the NAS report as the desired goal of any such collaboration 
between scientists and ethicists seems to indicate that this conversation is still aimed 
at formulating a united, better informed alliance aimed at persuading the public of the 
ultimate acceptability of gene therapy.  
 Another indication of how he was approaching the concerns of human 
enhancement can be found in how Kim Jin-Soo answered Kim Ok-Joo’s claim that 
all human genes are natural. He agreed that the human genome runs a very wide 
spectrum and there is no narrowly definable “standard state” that human genetic 
variety can be measured against; to quote the NAS report, “there is no single human 
genome shared by all of humanity.”96 However instead of concluding that there is 
nothing to correct towards, Kim Jin-Soo instead argued that the lack of a standard 
that there is no precise definition to distinguish between treatment and 
enhancement.97 A similar point was raised in the NAS report that I believe may shed 
light to his statement: as there is no standard state, all measurements of genetic health 
                                                 
발전할 수 있을 것이라고 생각합니다. 예를 들어서 미국 National Academy of Sciences가 올 
2월에 보고서를 냈죠. 인간 베아 연구를 어디까지 허용할 것인가에 관해서. 여기를 보시면, 
연구를 허용하는 것은 당연한 거고, 심지어 임상적용도 이러이러한 케이스는 허용할 수 있다, 
라고 돼있습니다. 그 보고서를 쓴 분이 Charo 박사님인데, 생명윤리학자입니다. 한국의 
생명윤리학자도 이 수준의 보고서를 충분히 쓸 수 있다고 생각합니다. 서로 돕고, 공부를 
하고, 논의를 하고, 그래서 연구자와 생명윤리학자와 철학자들이 팀워크를, 머릴 맞대서 
해결해야 하는 문제가 아닌가 생각하고… 예, 말씀 들어주셔서 고맙습니다.” Closing remarks, 
Kim Jin-Soo’s panel discussion, KAST roundtable.  
96 Human Genome Editing. p.124. 
97 “On the topic of enhancement and treatment, while those are of different concepts, to distinguish 




will be context-specific, and whether a particular case of human genome editing will 
turn out to be enhancement or treatment will depend on the circumstances. The report 
further observes that this distinction may need to be blurred in light of the evolving 
role of the physician from intervening in diseases already occurring to anticipating and 
preventing future diseases; preventive medicine can be categorized as both treatment 
and enhancement.98 In any case, as the particular strategy being pursued by the FARB 
team involves homology directed repair using a copy of the gene already in the cell 
and not anything designed by the physician, Kim Jin-Soo seems confident in his 
position that whatever he plans to do is not enhancement. 
 Compared to the two arguments earlier in the roundtable presented by Kim 
Jeong Hun, Kim Jin-Soo’s positions on the treatment/enhancement dichotomy are 
dismissive of the authority of naturalness. His alternative standard of “the 
normal/healthy state” is rather traditional for a scientist and stands in opposition to 
Kim Ok-Joo’s claim of universal naturality of all human genomes, a statement that he 
did not seek to argue against. He even goes as far as to say that what the current 
generation perceives as enhancement, and even the very notion that enhancement is 
bad, is not guaranteed to continue to hold for future generations, and that the standard 
may shift over time. Here he adopts a value-neutral approach to naturalness in that he 
concedes that all human genomes are natural, but in doing so he has made the criterion 
irrelevant to what genomes should be cured and what should be left as is. Worded 
                                                 
98 “Drawing lines: therapy versus enhancement.” Human Genome Editing. pp. 145-146. 
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differently, he merely seeks to replace natural but harmful genes with also natural 
genes that happen to be harmless. 
 For a point non-technical, naturalness is discussed rather often and at length 
by the medical scientists gathered at the KAST Roundtable; Kim Jeong Hun 
constantly returns to it, and it takes up nearly half of Kim Jin-Soo’s discussion as well. 
Kim Yon Soo, another of the panel speakers, also had something to say about 
naturalness, despite his discussion mostly dealing with the Korean Bioethics and 
Safety Law and its provisions for government-public oversight of scientist activity. A 
more in-depth look into his statement reveals that he is talking not of his views on 
naturalness but rather the views of the public. 
 
3.4. Negative connotations of “mutation” and the public’s irrationality 
Kim Yon Soo is a biomedical researcher at Chungnam National University’s Graduate 
School of New Drug Discovery and Development. Like Kim Jin-Soo, Kim Yon Soo 
is prolific in the media and a strong proponent of obtaining and maintaining a 
technological lead on gene therapy; to this end, he also argues for deregulation of 
research. As can be seen below, he brought the boldest deregulatory argument among 
the panel speakers at the KAST Roundtable. 
 Most of Kim Yon Soo’s discussion at the panel debate was centred around 
promoting a regulatory body composed of technical experts (i.e. bioscientists) to 
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control gene therapy, as opposed to a mixed or even non-technical body as currently 
provided for by the Korean Bioethics and Safety Act.99 As such, naturalness was not 
an explicit topic of his discussion; however, an indirect treatment of naturalness 
figured into his explanation of the opposition against gene therapy. Kim Yonsoo 
expressed his belief that the resistance of the general public against gene therapy was 
a result of either a misunderstanding or an unfounded fear, and naturalness, or more 
precisely “normalness” was part of that misunderstanding: 
…Another aspect of the [Korean Bioethics and Safety Act] that should be discussed is 
how it pivots on the term ‘mutation’. Most people when they see the word mutation 
would think of mutant traits. Of course, mutations are often positive, in some cases 
making cures possible. For instance, the gene therapy treatment of AIDS involves 
inducing a mutation on a ‘normal’ CCR5 gene so that it malfunctions. Science used 
‘gene correction’ to turn a normal gene into an abnormal state to achieve a cure for 
AIDS. The term mutation seems very negative at first glance, but [as just mentioned] 
actually has a lot of positive aspects. Whether a particular mutation is something safe 
and worthy enough to undergo clinical trial is something that a panel of experts can 
                                                 
99 Ethical oversight of bioscience research as required by the Korean Bioethics and Safety Act occurs 
at two levels, with a central National Bioethics Committee deliberating on matters of bioethics and 
safety, and Institutional Bioethics Committees in charge of oversight of actual research occurring in 
their respective institutions. Both are mixed bodies; the National Committee is composed of public 
servants, scientists, and “representatives of religions, ethics circles, judicial circles, non-government organizations or 
women”, while the Institutional Committees are mostly composed of members of the scientific 
institution itself but must include at least one member with “sufficient experience and knowledge to evaluate 
social and ethical validity” and at least one member from outside the institution. 
Korean Bioethics and Safety Act. Korean National Assembly Act, no. 14839 (2017). Retrieved from 






and do adequately judge. However, there are many in the public who are beholden by 
this ‘public fear’, civilians with negative impressions of genome engineering. I believe the 
use of words such as mutation in the law may be one of the causes of this fear, and 
thus, this word, along with the entire category, must be deleted from the law. […] 
Concerns regarding research are already sufficiently considered by relevant committees in 
charge of overviewing clinical trials, and they will disallow dangerous trials from going 
ahead. Regulations such as Article 47 are thus redundant, in addition to causing 
public fear, and are therefore undesirable.100 
Kim Yon Soo presents that one of the basis of public resistance against gene therapy 
is the public’s understanding that gene therapy involves “abnormal” mutations, which 
while abnormal are still beneficial. The word “normal” used by Kim Yon Soo in this 
context should probably be understood as additionally meaning “natural” as in 
“naturally occurring in the human genome”, as can be seen from how he describes the 
                                                 
100  Translated from the original statement in Korean. “또한 법의 문구에 변이[라는 표현이 
사용되는데]  이 변이라는 것이 많은 사람들에게는 돌연변이를 의미합니다. 돌연변이라는 
것은 어떤 측면에서 보면 굉장히 좋은 것인데, 인간에게 치료할 수 있는 좋은 것입니다. 
첫번째 유전자 치료기술을 이용해서 사람한테 적용한, 에이즈 환자가 에이즈 바이러스가 
T세포를 감염시키지 못하도록 정상적인 CCR5 유전자를 망가뜨리는 겁니다. 인위적으로 
유전자편집기술을 써서 변이를 일으킨거죠, 정상이 아닌 비정상으로. 그렇게 치료를 하고 
있는 겁니다. 변이라는 말은 우리가 대단히 부정적으로 들리지만 사실 양적(positive) 측면이 
많이 있는거고 이것이 [임상적으로 시험할 만한 것인지는] 위원회의 전문가들을 통해서 
충분히 볼 수 있는 것이기 때문에..  대중에게, 퍼블릭 피어(Public Fear)라고 우리가 보통 부르죠, 
유전자치료에 대하여 대단히 부정적인 견해를 담고있는 퍼블릭(대중), 일반인들이 많은데 
변이라는 부정적 용어가 우리의 인식을 일으키는 원인이 아닐까 생각합니다. 용어가 문제가 
아니라 사실 이 항목 전체가 없어져야 되는 것이고. 제가 주장하고 싶은것은 토론 말미에도 
나와있지만 사실은 얼마 전에 국무총리실에서 규제와 관한 의견을 내달라고 그래서 저는 
모든 항목을 없에라, 실제 사람에게 적용하는 것은 많은 주의가 필요하고 많은 논의가 
필요하지만 1,2 항은 없에는 것이 타당하다. 충분히 우리가 임상실험 인가 
커미티(Committee)에서 충분히 논의해서 결정할 수 있는 과학적 근거가 쌓여있고, 논의를 할 
수 있는 능력이 있기 때문에...” Kim Yon Soo’s panel discussion, KAST Roundtable. 
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CCR5 gene prior to gene therapy as “normal”. CCR5 refers to a chemokine receptor 
on human white blood cells that is used by many forms of the Human 
Immunodeficiency Virus to infect the cells, thus leading to AIDS. 101  Recent 
developments in gene therapy are targeting the CCR5 in an effort to achieve a curative 
(permanent) treatment of AIDS; 102  Sangamo Therapeutics’ ZFN gene therapy 
treatment SB-728-T is currently undergoing open label Phase 2 clinical study.103 This 
development is what Kim Yon Soo is referring to when he mentions deliberately 
turning normal CCR5 genes ‘abnormal’, which indicates that Kim Yon Soo was using 
“normalness” as a semi-synonym for “natural abundance”. While there do exist a 
naturally occurring, HIV-resistant version of the CCR5 receptor known as CCR5Δ32/Δ32, 
this is extremely rare especially outside of the European population groups.104 Seeing 
as a number of CCR5-centred gene therapy strategies – some of them undergoing 
                                                 
101  The connection between AIDS and the CCR5 gene has led to commercial interests rapidly 
capitalizing on its value, and eventually led to intriguing developments in intellectual property rights on 
human gene sequences. For a succinct summary of the history of the CCR5 gene and its 
commercialization see Jackson, M. W. (2015). How Gene Patents are Challenging Intellectual Property 
Law: The History of the CCR5 Gene Patent. Perspectives on science, 23(1), 80-105. 
102 Anjie Zhen and Scott Kitchen, "Stem-Cell-Based Gene Therapy for HIV Infection," Viruses 6, no. 
1 (2014), pp. 1-12. 
A review of their special pertinence in light of recent developments in antiviral medicine strategy can 
be found in:  
Stefan HE Kaufmann, Anca Dorhoi, Richard S. Hotchkiss, and Ralf Bartenschlager, "Host-Directed 
Therapies for Bacterial and Viral Infections." Nature Reviews Drug Discovery 17, no. 1 (2018), p.35. 
103 Sangamo Therapeutics, “Pipeline,’ https://www.sangamo.com/pipeline (retrieved 2019-04-01) 
Pablo Tebas, David Stein, Winson W. Tang, Ian Frank, Shelley Q. Wang, Gary Lee, S. Kaye Spratt et 
al., "Gene Editing of CCR5 in Autologous CD4 T-Cells of Persons Infected with HIV." New England 
Journal of Medicine 370, no. 10 (2014), pp. 901-910. 
104 Zhen & Kitchen, op. cit. p.3.  
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clinical trials105 – involve disrupting the expression entirely, Kim Yon Soo’s “abnormal” 
in this sense includes non-naturally-occurring forms as well. 
 What Kim Yon Soo is arguing in the above statement therefore can be 
understood as the assertion that naturalness is not equated with safety or desirability; 
in fact, desirable forms of some genes are desirable precisely because they are not 
natural. While this seems at conflict with Kim Jeong Hun’s invocation of naturalness 
at first, in light of how Kim Jeong Hun is painting a picture of a natural gene therapy, 
perhaps there is no contradiction. Kim Yon Soo’s argument is posed directly in 
opposition to the expectation that natural evolution has granted humanity with very 
good and efficient genes. This is the so-called “nature’s wisdom” argument, and Kim 
Yon Soo’s dismissal has some aspects that resonate with the dismissals by bioethicists 
quoted in the 2015 Nuffield Council report.106 Kim Jeong Hun’s argument is that his 
proposed gene therapy involves no insertion of foreign genetic material and minimal 
involvement of mechanisms not native to the human cell. As seen here, Kim Jeong 
Hun’s argument shares nothing with the nature’s wisdom argument that Kim Yon Soo 
attacks.   
 What’s interesting about the naturalness arguments being employed at the 
Roundtable is not in their differences but rather what they do have in common: that 
the concerns are being answered with technical solutions and clarifications, i.e. with 
                                                 
105 Ibid. p.4. 
106 Nuffield Council on Bioethics, Ideas about Naturalness. p.17. 
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science. Moreover, the scientists argue that more data, produced with further 
experiments, can only yield better science, and thus better answers for the questions 
currently being asked about biotechnology. Their arguments collectively paint the 
picture that all these concerns would not have been raised or could be soothed with 
proper, directed research. Scientists are eager to hear the concerns, they claim, and 
even more eager to look for relevant scientific findings so that they may answer those 
concerns. They merely want to be permitted to do so. 
 
4. The Public and the Authority of Science 
4.1. The positioning of the scientists’ arguments and the “Q&A” relationship 
A common element throughout the various arguments of naturalness brought forth 
by scientists at the KAST Roundtable is that they are all directed outwards; they are 
aimed at opposing viewpoints originating from outside the scientist community. These 
viewpoints are commonly held by the public, who were absent from the Roundtable 
itself – while historian of medicine Kim Ok-Joo was at the panel and raised issues of 
social justice, human dignity, and other ethical concerns, she raised no arguments 
dependent on naturalness itself, other than to point out that there is no single natural 
human genome (and thus no real way to easily discern “unnatural” human genes), 
which was the same point brought up by Kim Jin-Soo in the following panel 
discussion. These arguments from outside that the scientists were arguing against had 
been present in the wider genome engineering debate for some time; some of them 
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were those addressed by the international bodies being quoted by the scientists, such 
as the 2015 International Summit on Human Gene Editing,107 and some were those 
raised by critics of genetic engineering in books and political arguments.108 The reason 
there was practically no discussion occurring within the panel debate itself was because 
many of the arguments of the scientists were not aimed at Kim Ok-Joo; they were 
mostly speaking to or about the public that wasn’t there. 
  While the scientists make no specific mention of the arguments they had in 
mind when they presented their counter-arguments, I believe the following list more-
or-less represents the external arguments that correspond to each respective 
naturalness-based argument present at the roundtable: 
 “Wisdom of Nature” – arguing that humans should not intervene in natural 
processes that are the result of millions of years of evolutionary tweaking or divine 
design109 – corresponds to Kim Jeong Hun’s claim that his minimalist approach to 
gene therapy should be more attuned to natural phenomena. 
 “Purity of the Human Genome” – arguing that inserting foreign genetic 
material to the human genome insults human dignity, invades the sanctity of 
humanness, or raises unnecessary questions on what defines a human (and thus 
                                                 
107 National Academy of Sciences, International Summit on Human Gene Editing. 
National Academy of Sciences, Human Genome Editing. 
108 Hoongi Kim, The Right to Know and Right to Choose. 
109 Nick Bostrom and Anders Sandberg, "The Wisdom of Nature: An Evolutionary Heuristic for 
Human Enhancement," in Julian Savulescu and Nick Bostrom, eds., Human Enhancement (Oxford 
University Press on Demand, 2009). 
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defines eligibility for protection of human rights) 110 – corresponds to Kim Jeong 
Hun’s “non-transgenic,” or cisgenic, argument that his gene therapy involves no 
foreign genes. 
 “Anti-Enhancement Argument” – arguing that editing the human genome will 
lead to, or at the least allow the eventual proliferation of, human enhancement – 
corresponds to Kim Jin-Soo’s explanation that his gene therapy technique involves 
restoring the genome to a state already existent in the gene pool and therefore will not 
lead to “enhancement.” The human enhancement concern is a complex topic; 
bioethicists warn that enhancing the capabilities of some human beings beyond what 
is currently possible within the human gene pool may lead to either the rise of super-
humans as a separate class, or a shift in what is perceived as proper parental care. 
Existence of super-humans may create a new class struggle, which may exacerbate 
existing social divisions especially considering such technology may be beyond the 
reach of the economically underprivileged, and thus the genetically enhanced will also 
be economically better-off. Also, if enhancement were to become normalized, 
enhancement of some traits may become prevalent enough to be considered socially 
proper and thus individuals lacking those enhancement, such as those with inherited 
disabilities, may become ostracised.111 
                                                 
110 National Academy of Sciences, Human Genome Editing. p.124; Roberto Andorno, "Human Dignity 
and Human Rights as a Common Ground for a Global Bioethics," Journal of Medicine and Philosophy 34, 
no. 3 (2009), pp. 223-240. 
111 National Academy of Sciences, “Enhancement,” Human Genome Editing, pp. 137-162. 
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 “Wisdom of Repugnance” – arguing that genetically modified beings cause 
reactions of disgust among humans which in and of itself is sufficient moral grounds 
for opposition – corresponds to Kim Yon Soo’s arguments regarding the public fear 
of mutations, and may also correspond to Kim Jin-Soo’s argument that their therapy 
seeks to restore “normal” genes. The phrase “wisdom of repugnance” comes from 
Leon Kass, a physician and political activist who was chairman of the US President’s 
Council on Bioethics from 2001 to 2005.112 
 Due to this outwards focus of the panel arguments, the 112th Roundtable feels 
less like a policy discussion and more like a briefing on the current state of the debate 
delivered by active scientists to an audience of senior or retired scientists gathered 
there to check on the process – a briefing on what “they” are saying against “us”, and 
what arguments “we” have prepared to disarm those of the opposition. The outward 
directionality can be detected in the way the scientists describe their opposition, and 
the tone with which they present their own counterarguments. For instance, Kim 
Jeong Hun when describing how his gene therapy differs from previous ones, labels 
public impressions of previous techniques as “common misunderstanding,” as can be 
seen in the following quote: 
This has been an issue with gene therapy: gene therapy [in the past] involved solving 
problems with existing genome by introducing foreign sequences to replace problematic 
functions. While our technique is not too different from previous gene therapy [in its 
                                                 
112 Leon R. Kass, op. cit. 
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effect], it is commonly misunderstood that we also insert foreign genes to the 
genome to achieve our therapeutic goals. My research, including my clinical trials is not 
about inserting foreign genetic material into the cell. We are researching options that are 
considered normal parts of the natural metabolism of the cell, such as gene deletion and 
substitution. In this regard I argue that we are technologically safer than previous 
genetic therapies.113 
Kim Yon Soo describes public opposition to the concept of mutations as “public fear”: 
However, there are many in the public who are beholden by this ‘public fear’, civilians 
with negative impressions of genome engineering. I believe the use of words such as 
mutation in the law may be one of the causes of this fear, and thus, this word, along 
with the entire category, must be deleted from the law.114  
                                                 
113 “사실 이 부분은 유전자 치료가 가지고 있는 문제입니다. 유전자 치료는 기존의 유전자의 
문제를 해결하기 위해 외부의 유전자를 집어넣어서 이 문제 기능을 대신하게 하는 
방법입니다. 사실 생각해보면 그거랑 [유전자 교정 사이에] 큰 차이는 없는건데, 사실 우리는 
어떤 오해를 하고있냐면, 유전자 교정이라 하면 유전자 치료와 같이 하 새로운 유전자 하나 
집어넣어서 그런가보다, 라고 하지만, 앞서 말씀드린 많은 연구들, 그리고 제가 
임상의사로서 제가 진행하고 있는 연구는 요 부위는 전혀 하고 있지 않습니다. 저희는 
정상적으로 일어나는 현상 중 하나라고 생각할 수 있는 deletion, substitution 같은 굉장히 
안전한 방향으로만 가고있고 김진수 교수님과 제가 하고 있는 연구는 요 방향만 하고 
있습니다. 그게 일단 기술적으로 안전, 이라는 것이 첫번째 우리가 생각해야 할 부분이구요.” 
The “we” in the phrase 우리는 어떤 오해를 하고 있냐면(What we are misunderstanding) should be 
understood as referring to the Korean nation or society in the sense of the uninitiated public, as Kim 
Jeong Hun himself obviously understands the distinction between transgenics (insertion of foreign 
genetic materials) and cisgenics (use of native genetic materials). The phrase may also refer to non-
specialist scientists, but in this case the sense of being uninitiated still holds true. Kim Jeong Hun, 
presentation at the KAST Roundtable. 
114  “대중에게, 퍼블릭 피어(Public Fear)라고 우리가 보통 부르죠, 유전자치료에 대하여 
대단히 부정적인 견해를 담고있는 퍼블릭(대중), 일반인들이 많은데 변이라는 부정적 
용어가 우리의 인식을 일으키는 원인이 아닐까 생각합니다. […] 유전자치료에 대한 정의를, 
변이라는 표현을 대체해서 식약청의 유전자 치료에 대한 정의를 새롭게 냄으로서 충분히 
일반인들이 가지고 있는 막연한 공포는 없어질 것이라고 생각합니다.” Kim Yon Soo’s panel 
discussion, KAST Roundtable. 
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Such labels accompany the descriptions of opposing views, while “multitude of data 
(factual evidence)”115 and “communicative efforts (by experts)”116 are cited as means 
to combat those views. This characteristic positioning of the scientists is telling: the 
scientists are depicted as fighting against “misconceptions”, “assumptions” and 
“generalizations” that are invalided by scientific knowledge, especially the latest 
discoveries. 
 One could argue that there is nothing new with this mode of argumentation 
by scientists, relying upon their epistemological authority to persuade others, as this is 
in line with previous descriptions of the deficit model. I assert however that the 
authority of the expert society is not all that can be observed at work in these 
arguments, as the scientists are not arguing that they are already right per se, but rather 
that research is the only right way to gain valid information that in turn is necessary to 
make the right decisions, and thus research should always be allowed to proceed. 
While many scientists claim their acceptance of the public’s authority to decide the 
direction forward, as evinced Kim Jeong Hun’s statement that “the prevailing opinion 
                                                 
115  “그럼 왜 선진국들이 이렇게 우리나라보다 이렇게 이러한 새로운 기술에 대한 
임상실험이라던지에 대해서 더 보수적이지 않고 진보적인 입장을 취하느냐. 저는 그것이 
신뢰 기반의 사회에다가 히스토리를 중시[하기 때문이다라고] 생각합니다. 즉, 많은 
실험실에서의 데이터, 또 많은 임상시험을 통한 데이터가 있고, 그 데이터를 기반으로 해서 
전문가들이 모여서 아, 이 연구는 할 가치가 있다, 해볼만하다, 리스크가 비교적 없는 제품을 
통해서 들여다볼 필요가 있다 라고, 전문가들이 충분히 합의하면, 그것을 갔다가 실행할 수 
있게 하는 것이야 말로 선진국인 것입니다.” ibid. 
116 “결국에는 이런 유전자가위 연구자들과 생명윤리학자들 사이에 정보 공유와 소통이 정말 
중요 하다는 것이죠. […] 어떤 부분은 기술적으로 해결할 수 있을 것이고, 어떠한 우려는 그냥 
기우일 수도 있는 것이고, 생각을 통해서 해결할 수도 있을 것이고...” Kim Jin-Soo’s panel 
discussion, KAST Roundtable. 
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among scientists is that we should proceed with care until there is public consensus 
for the technology to move forward,”117 they are still insistent that proper decisions 
must be based on facts, facts that only science can provide. Even Kim Yon Soo, who 
argues that scientists are the only ones qualified to make decisions on what research is 
acceptable and what is not, grants that medical applications should be done “after 
careful consideration and discussion”; it is only research that should not be restricted 
by redundant oversight.118 It is in this vein that the scientists criticize the Korean 
Bioethics and Safety Act: it governs not only the practice of medicine but also research, 
hereby prohibiting scientists from obtaining critical data that can support more learned 
decisions regarding genome engineering.  
 That the moral valuation of nature was not questioned at the Roundtable is an 
interesting aspect of the scientists’ arguments. Outside of Kim Jin Soo briefly 
discussing the applicability of the word “natural” to the human genome, the scientists 
have not questioned the use of naturalness as a source of value; this is despite the 
usually observed trend of scientists being wary of giving the moral authority of nature 
too much credit, exemplified with Kim Yon Soo pointing out that naturalness itself 
                                                 
117 Translated from original Korean. “사회적인 consensus가 있기 전까지는 조심스럽게 하는게 
좋겠다, 라는게 현재까지의 동의입니다. 저도 거기에 동의합니다. 다만, 여기서 말하는건 
임상의 적용이구요, 연구는 할 수 있어야 하지 않나, 가 제 생각입니다.” Kim Jeong Hun, 
presentation at the KAST Roundtable. 
118  Translated from original Korean. “제가 주장하고 싶은 것은 토론 말미에도 나와있지만 
사실은 얼마 전에 국무총리실에서 규제와 관한 의견을 내달라고 그래서 저는 모든 항목을 
없애라, 실제 사람에게 적용하는 것은 많은 주의가 필요하고 많은 논의가 필요하지만 
1,2항은 없애는 것이 타당하다. 충분히 우리가 임상실험 인가 커미티(Committee)에서 충분히 
논의해서 결정할 수 있는 과학적 근거가 쌓여 있고, 논의를 할 수 있는 능력이 있기 때문에…” 
Kim Yon Soo’s panel discussion, KAST Roundtable. 
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has no inherent medical value in and of itself.119 The aforementioned 2015 survey 
report by the science policy research organization Nuffield Council is a quantification 
study showing a similar leaning on the part of UK scientists. The council’s report 
analysed the ways in which “naturalness” was utilized in arguments regarding genetic 
research in British publications for a period of 20 years up to the date of publication.120 
While categorizing the arguments by persons utilizing them, the Nuffield Council 
report found that the scientists under study made no value-laden mentions of 
naturalness, and instead showed an outspoken scepticism about there being a sound 
reason to assign right or wrong to naturalness (0 value-laden, 1% borderline).121 This 
is in marked contrast to value-laden usage of naturalness in other fields, such as in 
media articles (10% value-laden, 11% borderline), parliamentary discussions (12% 
value-laden, 7% borderline), and civil organization publications (6% value-laden, 11% 
borderline).  
 Comments from scientists as quoted in the Nuffield Council report suggest 
that the scientists become vocal about their avoidance of assigning value to naturalness 
when they encounter such value-laden conceptions being held by non-scientists. A 
2014 report published by the UK organization Sense About science on the topic of 
naturalness, for instance, posits that “in terms of chemical safety, ‘industrial’, 
‘synthetic’, ‘artificial’, and ‘man-made’ do not necessarily mean damaging and ‘natural’ 
                                                 
119 Aforementioned CCR5 argument by Kim Yon Soo, analysed in section 3.4. Kim Yon Soo’s panel 
discussion, KAST Roundtable. 
120 Nuffield Council on Bioethics, Ideas about Naturalness. 
121 ibid. pp. 41-45. 
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does not necessarily mean better.”122 Similar sentiment can be found in publications 
by US-based bodies as well: in a discussion document made for the National science 
Foundation, the authors pointed out that “…The natural-versus-artificial distinction, 
as a way to identify human enhancements, may prove difficult to defend given the 
vagueness of the term ‘natural’.”123 A relatively extended discussion of the topic and 
its place in the overall debate around genetic engineering can be found in the NAS 
report Human Genome Editing, where a similar sentiment is evident: “The word ‘natural’ 
has similarly taken on a positive connotation reflecting a common view that nature 
produces things that are healthier and generally better than anything artificial – this 
despite evidence demonstrating that ‘natural’ things can either be safe or intrinsically 
dangerous.”124 These arguments implore healthy scepticism against assigning value to 
naturalness itself.  
 Why is it, then, that the scientists gathered at the KAST Roundtable are 
making use of naturalness-based arguments? Why are they silent on the validity of the 
criterion of naturalness in the evaluation of the merits of gene therapy? Even if the 
public is worried about naturalness, shouldn’t scientists instead be concentrating their 
efforts into fighting the fallacies in imbuing value to nature, seeing as they are not the 
relevant questions? I believe this is because the scientists at the KAST roundtable are 
                                                 
122 Sense About science, Making Sense of Chemical Stories (2014) available at: 
http://www.senseaboutscience.org/pages/making-sense-of-chemical-stories.html  
123 Fritz Allhoff, Patrick Lin, James Moor, and John Weckert. "Ethics of Human Enhancement: 25 
Questions & Answers," Studies in Ethics, Law, and Technology 4, no. 1 (2010). 
124 National Academy of Sciences, Human Genome Editing. p.138. 
73 
 
accepting of the role of the public as ultimate decision-makers in the acceptance of gene 
therapy: as long as the concern is indeed being raised, it is not the place of scientists 
to question the validity of the concern. The scientists acknowledge the social validity 
of the concerns themselves, i.e. the related questions have been asked and many 
people are basing their decision-making on them, and so they can be persuaded by the 
scientists with successful and relevant answers. Kim Jin-Soo acknowledges that the 
public has concerns about the creation of babies endowed with “enhanced” traits, and 
promises that the gene therapy that he envisions has even less of a chance of such 
unnatural progeny. Kim Jeong Hun actively proclaims the naturalness of his gene 
knockout strategy in order to answer what he perceives to be common concerns in 
the public regarding the naturalness (and thus acceptability) of his new gene therapy. 
While Kim Yon-Soo warns against assigning value to naturalness itself, arguing that 
“unnaturalness” is not a valid ground for caution, he still grants that any medical 
application of the technology must follow thorough discussion and social 
consensus.125 
 These answers that scientists provide, along with their claim that further 
research must be allowed by the law to enable the discovery of further answers, 
present a relationship between science and the public that is different from, although 
not separate from, the traditionally understood relationship that underpins the deficit 
model. The deficit model directly correlates public resistance to science with public 
                                                 
125 Translated from original statement in Korean. “실제 사람에게 적용하는 것은 많은 주의가 
필요하고 많은 논의가 필요하지만…” Kim Yon Soo’s panel discussion, KAST Roundtable. 
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ignorance of science and seeks to remedy it with dissemination of knowledge on the 
contents and methods of science, with scientists deciding both the questions to be 
asked and the answers to them. In contrast, the relationship that the scientists at the 
KAST Roundtable imply is more akin to that of a Q&A session, with questions asked 
by the public which are then answered by the scientists. While the capacity to provide 
answers – their intellectual authority – is still closely guarded by the scientists, it is the 
public that decides what questions the public is concerned about. Even though the 
public was absent from the Roundtable itself, by directing their efforts to answering 
what they perceived as public concerns the scientists interacted with public opinion, 
albeit in an admittedly long-winded and roundabout way. Rather than telling the public 
what they should understand, science asks the public what it wishes to know. 
 The aforementioned positioning explains to the audience why it is worthwhile 
to support the work of the scientists, but what form should that support take? How 
do the scientists want to be supported? The scientists were clear in their demands: 
they want deregulation. 
 
4.2. History of the Korean Bioethics and Safety Act and the Legacy of Hwang 
As can be seen in the title of the 112th Roundtable Discussions, the overall focus of 
the scientists’ collective arguments was that the current Korean Bioethics and Safety 
Act must be made less restrictive of research. Describing the current regulations with 
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adjectives such as “counter-productive,”126 “most conservative,”127 “backwards,” and 
“misunderstanding,”128 the scientists argued that there was little justification for the 
level of restriction placed on gene therapy research. 
 The scientists’ arguments of deregulation are not themselves the focus of this 
paper and will not be analysed in detail here. However, the legal and social context in 
which the current deregulatory push is placed are of interest, especially regarding the 
changing narratives with which the scientists’ role within society has been framed in 
the understanding of the Korean public. The “Q&A” posture taken by the scientists 
in regard to naturalness-based arguments, and the eagerness on part of the scientists 
to present themselves as good listeners that this posture represents, should be 
understood in relation to the increasing “public distrust” that scientists perceive within 
Korean society. 
 The Korean Bioethics and Safety Act, and legal governance of bioscience and 
biotechnology in general, has been characterised by a tug-of-war between the two 
positions of “promotion of Korean biotechnology” and “protection of human values”, 
each championed by bioscientists and bioethicists respectively. In the network analysis 
of various actors and the interactions between them in the original 2005 legislation of 
the Korean Bioethics and Safety Act, Science and Technology Studies scholar Song 
                                                 
126 Scientists argue that the new law protects neither the welfare nor the rights of citizens. 
127 Kim Yon-Soo claims that the Korean law is based on some of the most conservative laws regarding 
gene therapy in the world, for instance that of Japan. 
128 The “non-transgenic” argument of Kim Jeong-Hun asserts that the legislature lack understanding 
of the distinction between previous genome engineering techniques such as recombinant DNA 
technology and the current CRISPR-aided gene knockout strategy pursued by his team. 
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Sung-Soo explains that the non-government actors can largely be divided into the 
science community and the citizen advocacy groups, each arguing for promotion of 
biotechnology and protection of human values, respectively. The deliberations 
surrounding Bioethics and Safety Act in the early 2000s were characterized by the 
constant and unresolved stand-off between these two positions. This stand-off caused 
constant delays in the legislative process, and the proposal went through numerous 
revisions while the positions of the bioscientists and the NGOs remained unchanged 
throughout the time period. Legislation was achieved only after the non-government 
actors were deprived of their access to the legislative process and the divisions within 
the government were temporarily set aside in favour of not delaying the legislation any 
further. The resulting law reflected mostly the views that favoured the promotion of 
biotechnology.129 
 In his book Biotechnology and Politics bioscience journalist Kim Hoongi analyse 
the actors and concerns that were involved in the earliest formulative stages of the 
Bioethics and Safety Act, between the late 90s and its first legislation in 2005. The 
main actors in the Korean legislative process are the Standing Committees of the 
National Assembly, which dominate the legislative process within the legislature, and 
the relevant Ministries of the executive branch of the Korean government. In the case 
of the Bioethics and Safety Act the actors are the Science, ICT, Broadcasting, and 
Communications Committee of the National Assembly (hereafter referred to as the 
                                                 
129  Sungsoo Song, “Policy Network Analysis on the Legislation Process of Bioethics in Korea, 
1997~2003,” Journal of Korea Technology Innovation Society 8, no. 2 (2005), pp. 702-731. 
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Science Committee), the Ministry of Science and Technology (underwent numerous 
reorganizations in recent history, currently the Ministry of Science and ICT), and the 
Ministry of Health and Welfare. Kim Hoongi reports that the Science Committee 
favoured the statist arguments for the promotion of biotechnology over the moralist 
arguments for the protection of human values, which were championed mostly by 
citizen advocacy groups, who did not have direct access to the Committee. The 
Ministry of Science and Technology followed suit for the most part and worked to 
represent the opinions of the Korean science community. The Ministry of Health and 
Welfare, although representing the arguments of the human values advocacy groups 
at first, realized quickly that any legislative proposal that ran contrary to the opinions 
of the science community was unlikely to be approved by the Science Committee, and 
shifted their position to be more in-line with the rest of the main actors. Kim Hoongi 
observes that while both ministries were eagerly pushing for new legislation that would 
govern bioethics and biosafety (a push encouraged in part by the Cartagena Protocol 
on Biosafety), neither had “specific vision” on what form the new law should take, 
which is why the ministries were quick to fall in line with the view of the Science 
Committee.130 
 This changed drastically in the 2012 revision of the Bioethics and Safety Act, 
which more-or-less completely overhauled the law and reoriented it away from the 
promotion of biotechnology and towards the protection of human values. Legal 
                                                 
130 Hoongi Kim, Biotechnology and Politics (Seoul: Whistler, 2005). 
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scholar Cho Hong Suck writes in his analysis of the 2012 revision of the Korean 
Bioethics and Safety Act that the deletion of “establishing circumstances that would 
promote [biotechnology]” from the mission statement of the Bioethics and Safety Act 
(Article 1), thus leaving only “preventing the harming of human bodies and the 
violation of human dignity and values”, is crucial and reflects the overall theme of the 
2012 revision. In addition, the revised law postulates that all subsequent laws that 
govern matters of bioethics and biosafety must obey the principles and regulations set 
forth in the Bioethics and Safety Act, which affirms that the law’s new focus on the 
promotion of human values is comprehensive and must be observed by everyone at 
all cases within Korean jurisdiction. This shift in focus was accompanied by a much 
stronger system of oversight on research activities, with the oversight committees now 
mandating the inclusion of “experts on bioethics”.131 
 It is this revised form of 2012 that is under discussion at the 112th Roundtable 
Discussions. Article 47 is of particular interest, as it governs gene therapy specifically. 
As explained briefly in section 3.2 while discussing Kim Jeong Hun’s arguments, 
Article 47 prohibits all gene therapy activity unless the particular activity meets the 
two criteria set forth within the article. The first criterion is the “disease criterion”, 
allowing gene therapy for genetic diseases, cancer, AIDS and other such critical, life-
threatening diseases. The second criterion is the “method criterion”, allowing gene 
therapy for diseases where no other methods of treatment exist, or gene therapy is 
                                                 
131 Hong Suck Cho, op. cit. 
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expected to be substantially superior to all existing methods. For in-vivo therapy, both 
criteria have to be met, while for ex-vivo only one of the two criteria need to be met. 
In its 2005 original form the Korean Bioethics and Safety Act originally required only 
one of the two criteria be met for gene therapy to be allowed; this was changed in the 
2012 overhaul to require both criteria be met in response to calls for stronger 
regulation, but then partially deregulated for ex-vivo therapy in 2015 in consideration 
of the “international deregulatory trend”.132 
 Throughout this period the constant tug-of-war between the two positions of 
promotion of biotechnology and protection of human values is evident within the law 
itself, even after the deletion of the former position from the mission statement in the 
2012 revision. The 2015 revision, for instance, list “improving national competence in 
the gene testing field” as one of the reasons for the deregulatory revision.133 This 
shows that the position of the scientists at the Roundtable, that the Bioethics and 
Safety Act should promote biotechnological advancement despite the contrary stated 
mission of the law, is not unique to the scientists and enjoy, or at least have enjoyed 
in 2015, considerable support within the government. 
 A turning point in this tug-of-war was the Hwang Woo Suk scandal that 
rocked Korea in 2005. Science historian Song Sang-Yong analysed the Hwang scandal 
                                                 
132 Dae-Woong Park and Hwa-Shin Ryoo, “Regulatory Framework for Gene Therapy on Human 
Embryos in Response to CRISPR-Cas9,” Journal of the Bioethics Association 17, no. 1 (2016), pp. 35-52. 
133 Original text is in Korean, translation is mine. Bioethics and Safety Act. Korean National Assembly 




as one of the largest crises in the history of Korean science, and a turning point in the 
struggle between scientism powered by an “ideology of development”, which would 
correspond to the call for promotion of biotechnology, and the concern over 
protection of human values. Hwang Woo Suk is a Korean veterinary scientist who 
first gained fame in 1999 for his claim of cloning two cows, dairy cow Yeongrong-I 
and Korean cow Jin-i. His alleged claim of creating an embryonic stem cell in 2004 
gained him international notoriety, and he became the greatest, most celebrated hero 
of Korean science. When his 2004 and 2005 publications were proved to be the results 
of academic fraud, and that he had achieved practically none of the things he had 
claimed to have achieved, shocked the nation, but defence of Hwang’s research and 
reputation continued for some time and still remain active to some extent. Noting that 
celebration and defence of Hwang Woo Suk transcended politico-ideological divides 
and social categories, Song Sang-Yong argued that Hwang’s popularity was a symptom 
of widespread belief in scientism that permeated the whole of Korean society. While 
the fall of Hwang provided an opportunity for Korean society to re-evaluate scientism 
and its development-focused outlook, Song writes that scientism still reigns strong in 
Korea and its effects are constantly felt.134  
 Hwang had been linked with the Korean Bioethics and Safety Act from its 
early legislation. As Kim Hoongi notes, the concern that regulation of genome 
engineering research could hamper Hwang’s research efforts was one of the strong 
                                                 
134 Sang-Yong Song, “The Hwang Woo Suk case: A Critical Review,” Korean Association of Science and 
Technology Studies Conference 2015.12 (2015), pp. 1-11.   
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factors influencing the legislative process.135 His fall from grace, in turn, created a 
strong social impetus for increased outside oversight on bioscience research, which is 
noted as one of the reasons for the 2012 revision of the Bioethics and Safety Act, and 
numerous other laws covering similar issues of bioethics.136 Hwang remains the most 
remembered case of the excesses of Korean scientism, and a prototype of what future 
science governance should avoid. 
 Constant references to “distrust” of scientific authority on part of the Korean 
public alluded to by the scientists of the 112th Roundtable thus should be understood 
in reference to the legacy of Hwang. The scientists’ appeals to statist-scientist 
arguments such as national scientific competence belies the continued influence of 
“development ideology” and scientism among Korean bioscientists, as noted by Song 
Sang-Yong. From this point of view, the 2012 revision represents an “over-reaction” 
of Korean society (of which the state is considered a representative agent) towards the 
scientific community over the peculiar wrongdoings of a single scientist, who has 
already been disenfranchised and cast out. 
 Furthermore, evidence suggests that scientists understand the legacy of 
Hwang to be primarily about his research fraud, and show less interest in the 
accusations of bioethical nature, such as regarding the morality of Hwang’s harvesting 
of eggs from his junior scientists and economically unprivileged patients, and the 
                                                 
135 Hoongi Kim, Biotechnology and Politics, section 3, pp. 96-167. 
136 In-Young Li, “Legal Policy for Genetechnology – Promotion, Biosafety, Bioethics,” Hallym Law 
Forum 18 (2007), pp. 157-197.  
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matter of whether sufficiently informed consent was given. Kim Yon Soo’s argument 
that the peer-review process is sufficient and the lack of scientific expertise on part of 
outside panels makes them unfit to understand and judge research, also stand on the 
assumption that most activities of the review board will centre around inquiries of 
technical nature, not moral.137 Kim Jeong Hun’s comments regarding the applicability 
of the Bioethics and Safety Act to him, when he claimed that he’s “not doing this to 
publish ‘good’ papers”, also may be alluding to the Hwang scandal as it relates to the 
Bioethics and Safety Act. While explaining that his research cannot meet both criteria 
for allowed research as set forth in Article 47 of the Bioethics and Safety Act, Kim 
Jeong Hun remarks, “I am not a basic researcher, I do clinical studies and applied 
research to bring new technologies to my patients. This law prohibits my research, but 
I’m not doing this to write good papers or anything like that.” By differentiating 
himself from ‘pursuit of academic accolades’, Kim Jeong Hun is arguing that he is not 
someone that the law should be aiming to regulate.138 
 The use of naturalness arguments by scientists at the Roundtable Discussions 
represents a shift away from this focus on the science vs. ethics dichotomy that 
characterised previous stand-offs between “promotion of biotechnology” and 
“protection of human values”. Whereas the two concerns had been understood to be 
in constant conflict with each other, scientists’ attempts at answering naturalness-
                                                 
137 “Concerns regarding research are already sufficiently considered by relevant committees in charge 
of overviewing clinical trials, and they will disallow dangerous trials from going ahead.” Kim Yon Soo’s 
panel discussion, KAST Roundtable. 
138 Kim Jeong Hun, presentation at the KAST Roundtable. 
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based concerns with scientific counter-points and the resulting “repositioning” of the 
utility of science in regards to societal concerns represents a marriage of the two 
positions into a single narrative, where promotion of biotechnology (technically, 
bioscientific research) is protection of human values. While this still stays firmly within 
the overarching ideology of scientism, this new posture deviates from simplistic 
characterisation of ethics “getting in the way of progress” and thus could be a sign of 
more conversational approaches in the future. 
 
4.3. Appeal to the authority of the NAS report and Asilomar-in-Memory 
Most, if not all, of the arguments scientists presented in regard to naturalness concerns 
at the Roundtable were adopted from the arguments analysed and set forth in the 
NAS report Human Genome Editing. There are also multiple other similarities that can 
be drawn between the positioning of the scientists at the KAST roundtable and the 
emphasis on the need to allow research to proceed presented by the 2017 NAS 
report.139 First of all, the scientists at the roundtable constantly cite both the report 
and the 2015 International Summit that ultimately led to it as sources of authority to 
boost the persuasiveness of their claims for deregulation. There are numerous points 
in the Roundtable where the scientists bring up the Summit on the report as evidence 
of international consensus among scientists that some avenues of genetic research are 
                                                 
139 National Academy of Sciences, Human Genome Editing. 
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safe enough to pursue, as shall be seen in more detail below. In addition, the Summit 
is taken up as proof that scientists are aware of the concerns of the public and are 
actively discussing and addressing the concerns, especially with Kim Jin-Soo who was 
present at the 2015 Summit and participated in the deliberations. This is especially 
visible with the arguments of Kim Yon Soo who pushes for more autonomy and self-
regulation for scientists when it comes to research. 
 There’s also a rather intriguing connection that can be found in the way 
scientists in the KAST roundtable and the NAS argue for the importance of 
continuing research. In addition to the above arguments that research is safe and that 
scientists can be trusted, a third argument regarding why research should be done is 
presented that is in line with the aforementioned “answering of questions”. The more 
interactive relationship between science and the public that I described above centres 
around a re-positioned claim for science’s sole capacity to provide meaningful answers. 
The claim that science is the sole source of verifiable (or at the least, intellectually 
valuable) answers is defended by the assertion that valid decisions are those based on 
facts, the traditional demesne of science. Kim Jeong Hun argues that research of gene 
therapy techniques should be allowed regardless of current regulatory status of their 
medical application, as the decision to deregulate or not would itself have to rely on 
the answers that science will find.140 While he does not directly weight in on the need 
                                                 
140 Translated from original Korean. “다만, 여기서 말하는 건 임상의 적용이구요, 연구는 할 수 
있어야 하지 않나, 가 제 생각입니다. 연구를 해야 그 다음에 필요성을 알 텐데…” Kim Jeong 
Hun, presentation at the KAST Roundtable. 
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for science to be allowed to find answers, Kim Jin-Soo emphasizes the importance of 
bioethicists to interface directly with scientists so that their concerns may be 
thoroughly discussed, understood, and answered using relevant scientific knowledge 
– which implies the importance of finding that knowledge. 141  This emphasis on 
allowing research bears intriguing similarities with prior research regarding the way 
scientists remember the recent past of bioscience. 
 The aforementioned assertion of the need for fact-based decision-making and 
the supremacy of science as the source of facts are in line with a certain worldview 
common among scientists, which is called the “received understanding” by Susan 
Wright in Molecular Politics and “Asilomar-in-memory” by J. Benjamin Hurlbut in 
Remembering the Future. Molecular Politics reports that the history of deregulation of 
recombinant DNA technology is remembered and understood by scientists as being 
primarily a result of educational and persuasive efforts by scientists, fighting 
misunderstandings based on incomplete knowledge. Wright reports that a biased view 
of the history of Bioscience was at work among scientists, the aforementioned 
received understanding;142 in this version of history, the deregulation of biotech after 
initial public resistance is depicted as being the result of successful efforts by scientists 
to persuade non-scientists of the lack of merit of previous concerns. Hurlbut links this 
                                                 
141 Translated from original Korean. “결국에는 이런 유전자가위 연구자들과 생명윤리학자들 
사이에 정보 공유와 소통이 정말 중요 하다는 것이죠. […] 서로 돕고, 공부를 하고, 논의를 
하고, 그래서 연구자와 생명윤리학자와 철학자들이 팀워크를, 머릴 맞대서 해결해야 하는 
문제가 아닌가 생각하고…” Kim Jin-Soo’s panel discussion, KAST roundtable. 
142 Wright, op. cit. p.7.  
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view of Asilomar with the 1995 US Congressional hearings on cloning technology and 
2010 Presidential Commission on Bioethics, arguing that Asilomar as remembered by 
scientists and key persons in governance served as a model for both cases, prescribing 
what form proper governance takes, involving a fixed relationship between science, 
government, and the public. A new ideology was in place, providing instructions for 
building a better future. 
 The received understanding of Asilomar as analysed by Wright goes as follows. 
The arguments for opposing genetic engineering that were key to the guidelines 
imposed in the aftermath of Asilomar were then found by scientists to be based either 
on lack of knowledge on the subject or on faulty, subjective reasoning. Concerted 
education using newest research findings filled in the gaps in the public understanding, 
or at the least persuaded policy makers to listen to reason instead of fear. In this way, 
deregulation was not spawned from negotiation but was the cumulative result of 
cooler heads eventually prevailing; it was society, not science, that was the primary 
source of risk. Wright’s book demonstrates in detail just how much negotiations and 
changing of circumstances were involved in the actual process of deregulation; 
nevertheless, the received understanding continues to dominate scientists’ perception 
of past events, including the Asilomar conference itself. 
 This “received understanding” can be better understood in relation to the 
long-held narrative of “Public Understanding of science”, which centres around 
attempting to bridge a gap in understanding and perspective between “science”, as 
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understood as a unified body of specialists, and “the Public”, imagined as a mass of 
laypersons with no expert knowledge. Much of the efforts by scientists and 
government bodies in bringing the public into science governance, including efforts 
for increased public participation, has been handled under the umbrella of that 
narrative. Monika Kurath and Priska Gisler in their work Informing, involving or engaging? 
science communication, in the ages of atom-, bio- and nanotechnology offers a critique of this 
narrative and efforts associated with it, pointing out that this simplistic opposition 
between two imagined, antagonistic bodies of thoughts is what drives the 
ineffectiveness of the efforts in the first place. Analysing the various technological 
controversies in the late 20th and the current centuries, Kurath and Gisler note that, 
even as the narrative of Public Understanding constantly shifted towards a “more 
democratic form of participation” by the public in scientific governance, the essential 
epistemological divide between an expert scientific community and a relatively 
underinformed “lay” public was maintained, which perpetuated the one-directional 
“deficit” model of knowledge dissemination.143 Key to this continued survival of the 
deficit model in some shape or form would be the collective memory of Asilomar that 
various relevant groups hold. Gisler and Kurath noted that, while the specific contents 
were different, state officials, scientists, and NGO activists alike remembered the 
Asilomar conference fondly as an example of responsible governance and 
                                                 
143 Kurath & Gisler, "Informing, Involving or Engaging?" 
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participation; a “paradise lost”.144 All subsequent interactions between science and the 
public were understood in relation to the first “model” case. 
 J. Benjamin Hurlbut in Remembering the Future explains that such a perceived 
understanding of the context and achievements of Asilomar, “Asilomar-in-memory”, 
prescribed both a proper form of responsible governance of emerging technologies 
and proper levels of agency to the Scientific Community, the State, and the Public.145 
Utilizing Jasanoff’s theorization of Sociotechnical Imaginaries that are fleshed out in 
the same book, Hurlbut describes that not only is Asilomar-in-memory an imagined 
ideal past but a powerful prescription for handling all emerging technologies, 
representing a success story that is to be emulated in order to ensure the continuous 
ushering in of productive futures, brought about by the new technology. Analysing 
the 1997 Congressional hearings on cloning and the deliberations of the 2010 report 
of the Presidential Commission for the Study of Bioethical Issues, Hurlbut explains in 
succinct detail how Asilomar-in-memory was crystalized into a stable system: in it, 
science is an autonomous, self-governing and unified body that is solely competent to 
“read” and foretell the future. Law is understood as necessarily reactive to the changes 
brought about by science due to its lack of expertise; thus, law should patiently wait 
while science produces the knowledge necessary to understand what possible futures 
exist. In turn, science is to responsibly practice its autonomy and serve society by 
                                                 
144 Gisler & Kurath, "Paradise Lost?” 
145 J. Benjamin Hurlbut, "Remembering the Future: Science, Law, and the Legacy of Asilomar," Sheilla 
Jasanoff and Sang-Hyun Kim, eds., Dreamscapes of Modernity: Sociotechnical Imaginaries and the Fabrication of 
Power (Chicago: University of Chicago Press, 2015), pp. 126-151. 
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carefully measuring the risks and benefits of expanding technology: the Asilomar 
moratorium as initiated by the Berg Letter 146  is hailed as the exemplar of such 
responsible action. Notably, the public is imagined as an unruly entity prone to acting 
prematurely; it must be carefully managed so that discussions on how to proceed can 
occur only after science produces its predictions of possible futures. The role of 
government is to act as the crucial bridge between the concerns of the public and the 
knowledge of science; to relay the worries of the public to science, to support and 
allow science to find answers, and to manage the public so that its concerns do not 
boil over into rash action. This tripartite division of labour is designed to ensure that 
the public’s sometimes overreactive, potentially destructive imaginations do not result 
in harm to the whole. Asilomar-in-memory is a shining success story of this particular 
form of governance, and by re-enacting it, society perpetuates the set roles prescribed 
by the memory to the three primary actors.  
 There are similarities that can be drawn between the model prescribed by 
Asilomar-in-memory and the argumentative positions took by the scientists at the 
KAST Roundtable. While none of them invoke the image of Asilomar directly, they 
constantly remind the audience that the key tenets of good governance are to seek the 
right answers. Kim Jeong Hun argued that allowing research to proceed can only lead 
                                                 
146 Paul Berg, David Baltimore, Herbert W. Boyer, Stanley N. Cohen, Ronald W. Davis, David S. 
Hogness, Daniel Nathans et al., "Potential Biohazards of Recombinant DNA Molecules," Science 185, 
no. 4148 (1974), p.303. 
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to better tools and better answers.147 Kim Jin-Soo points out that bioethicists (in the 
governance position) should reach out to scientists and communicate the concerns 
that they and the public have so that scientists can properly answer them.148 Kim Yon 
Soo emphasizes the role and prominence of the expert committees charged with 
policing research in the US, and the trust that government has placed in the 
scientists.149 
                                                 
147 Translated from original statements in Korean. “다만, 여기서 말하는건 임상의 적용이구요, 
연구는 할 수 있어야 하지 않나, 가 제 생각입니다. 연구를 해야 그 다음에 필요성을 알텐데 
제가 알기론 미국이나 스웨덴의 연구팀에선 연구는 허용된 걸로 압니다.” Kim Jeong Hun, 
presentation at the KAST Roundtable. 
“다시 말해서, 유전자 교정 기술이 개발되면 개발될수록 Off-target effect 라는건 줄어들 
수밖에 없고요, 연구자가 더 유전자 교정을 연구해서 더 잘 만들면 당연히 Off-target effect는 
(줄어들 거기 때문에) 저희가 걱정하고 유려하지만, 오히려 조금 더 긍정적인 눈으로 바라볼 
수 있는 부분이 아닌가 생각합니다.” ibid. 
“지금 현재 진행하고 있는 실험도 그렇고 원숭이 실험도 그렇고. 그런데 제가 한가지 
걱정하는 것은 저희가 이런 연구를 하는 데에 있어서 물론 무조건 무조건 해야 됩니다, 뭐 
안전합니다 라고 강조하고 싶은 게 아니고요, 이런 연구가 잘 적용될 수 있도록 저희가 지금 
front에 가 있다고 생각하면, 더 front로 앞서나갈 수 있도록, 이 연구가 발전할 수 있는 계기가 
되기를 정말 염원하구요. 이 토론에서 제가 도움을 받을 수 있는 많은 말씀을 들을 수 있기를 
기원하겠습니다. 이상입니다.” ibid. 
148 Analysed earlier in section, and also in section 3.3. Kim Jin-Soo’s panel discussion, KAST roundtable. 
149  Translated from original statement in Korean. “마지막으로 말씀드리고 싶은 것은 [일반 
신약개발에 대한 허가는 식약청(FDA)에서 하지만] 유전자 치료 기술에 대해서는 NIH에서 
민간 위원회를 통해서 허가합니다. RAC(Recombinant DNA Advisory Committee)이라고 해서 
25 명 내외의 민간 전문요원들이 심의를 합니다. 20 년 가까이의 히스토리, 심의 역사를 
통해서 "아 이거는 우리가 심의를 안해도 임상 연구 할 수 있어"싶은 항목에 대해서는 심의도 
안하고 바로 허가를 내줍니다. 하지만 새로운 유전자 기술, CRISPR 기술과 같은 것이 오면, 
"아 이건 우리가 한번 들여다봐야해" 하고 들여다보고 심의를 해서 "아 이건 할 수 있겠어" 
하면 바로 허가해주고 식약청은 자기네가 가진 기준을 가지고 자료를 요구해서 심의한 다음 
허가를 해 줍니다. 그 특징중의 하나는 NIH 에서 유전자치료에 대해서 심의하는 
전문요원들은 25 명 모두가 실명이 공개가 되고 거기서 토론하는, "이 심의대상 연구를 
허가할 것인가 추가 데이터를 요구할 것인가" 토론하는 내용이 카메라로 모두 recording되서 
모든 사람이 볼 수가 있습니다. 그래서 신뢰, 전문성과 신뢰성을 확보한 상태에서 하고 있죠. 
따라서 식약청이 따라갈 수가 없는 새로운 기술에 대한 판단은 NIH에서 전문가를 통해서 
임상시험을 허가를 해줍니다. [미국에] 우리나라 생명윤리법에 있는 1,2항과 같은 조항은 
없습니다. 다만 있는것은 베아, 생식세포에 대한 것은 제한하지만 그것도 연방펀드를 가진 
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 Further connection between Asilomar-in-memory and the arguments at the 
KAST Roundtable can be found through the constant references to the 2015 
International Summit and the NAS report Human Genome Editing. 150 Kim Jeong Hun 
and Kim Jin-Soo invoke the authority of the International Summit (in which Kim Jin-
Soo took part) and the resulting Human Genome Editing report as evidence of the 
existence of broad, authoritative consensus among scientists about what kind of 
research should be allowed to proceed. Seeing as the International Summit is in many 
ways a successor to the spirit of the Asilomar Conference, having been summoned by 
a similar call for moratorium, the 2015 Baltimore letter, written by many of the same 
people, including Paul Berg,151 the scientists of the KAST roundtable can be said to 
be invoking a modern re-enactment of the Asilomar conference, in an attempt to re-
establish the proper form of science governance as prescribed by the received 
understanding. Kim Jin-Soo’s glowing reference to bioethicist Alta Charo, one of the 
key persons involved in the 2010 Presidential Commission that Hurlbut studies, may 
also be understood in line of these connections. Charo is one of the co-authors and a 
spokesperson for the conclusions of the 2017 report, as seen in a Proceedings of the 
NAS interview. 152  In his praise, Kim Jin-Soo laments that there hasn’t yet been 
                                                 
연구만 제한되지 민간 펀드를 사용한 연구는 제한되지 않습니다.” Kim Yon Soo’s panel 
discussion, KAST Roundtable. 
150 National Academy of Sciences, International Summit on Human Gene Editing. 
National Academy of Sciences, Human Genome Editing. 
151 David Baltimore, Paul Berg, Michael Botchan, Dana Carroll, R. Alta Charo, George Church, Jacob 
E. Corn et al., "A Prudent Path Forward for Genomic Engineering and Germline Gene 
Modification," Science 348, no. 6230 (2015), pp. 36-38. 
152 Prashant Nair, op. cit. 
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someone like Charo in Korea, who would defend the importance of continuing 
research in the name of finding answers – an argument that Charo herself had done 
by invoking Asilomar-in-Memory. 
 Kim Jeong Hun in his presentation emphasizes that the International Summit, 
while voluntarily committing to David Baltimore’s proposed moratorium on germline 
editing,153 gave the green light on somatic cell edits, which he claimed was supportive 
of his argument for deregulation in Korea. Kim Yon-Soo explicitly claims that 
scientists are already empowered to govern themselves, and that further regulatory 
oversight without scientist input is redundant and harmful to society. They stress that 
the inhibition of science, caused by the premature intervention of Law, will come back 
and lead to great losses by the public. Instead, they argue, research itself must continue, 
even if the public ultimately decides to not implement gene therapy in practice; if that 
comes to pass, at the least it will be a learned decision, informed by the results of 
scientific research. This argument echoes that of Asilomar-in-memory: as Alta Charo 
told the US Senate Subcommittee on Labour and Human Resources in 1997, “these 
kinds of … discussions about the scientific advances that are at risk if we were to ban 
all such forms of research could be more important than any kind of legislation you 
ultimately come up with, because it will help us to understand what it is we are 
balancing and make a reasoned choice.”154 
                                                 
153 David Baltimore et al., op. cit. 
154 Re-cited from J. Benjamin Hurlbut, op. cit. p.139. 
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 In this vein, the opposition of the scientists at the Roundtable to the Korean 
Bioethics and Safety Act gains a new dimension. The scientists argue that the law has 
been “imposed” on an unwilling scientific community, without its consent or input, 
and that this imposition is harmful.155 In reference to Asilomar-in-memory, such an 
imposition would be a grave trespass, as not only has law acted prematurely, without 
having all the answers in hand, but it has also prohibited science from providing 
further knowledge. In order for science to readily serve its rightful role, research must 
be deregulated as in accordance with the consensus of the 2015 International Summit, 
the newest incarnation of Asilomar. Any further concerns of the public would then 
be answered by this new research; only after the answers have been provided should 
law act. 
 
5. Conclusion: Scientists of the Roundtable 
The scientists gathered at the 112th KAST Roundtable Discussions argued many 
things on gene therapy’s behalf. Analysing their naturalness-based arguments in 
particular, I noticed how the arguments, while not fully developed, still engaged 
properly with naturalness-based concerns of the public. This was despite a noted 
                                                 
155  Translated from original text in Korean. “그러나 이러한 제도화는 ‘추격형(fast follower), 
하향식(top-down)’ 방식의 특징을 보이며 한계를 드러내고 있음. 우리나라의 제도는 
외국에서 수십년에 걸쳐 논의되고 발전한 소위 ‘선진’제도를 빠르게 수입하여 따라잡고자 
하였다는 점에서 추격형이며, 관련 연구자와 학문 공동체는 대체로 제도 도입에 소극적, 
방어적이었던 반면 정부가 주도하여 제도의 도입이 추진되었다는 측면에서 하향식임.” 
Korean Academy of Science and Technology, Medical-Life-Sciences and Human Rights. 
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tendency on part of scientists to be reluctant to invoke naturalness or express 
scepticism over its moral value, perhaps in knowledge of the various pitfalls that 
naturalness as a moral authority is associated with. While the scientists did not agree 
among themselves regarding the precise valuation of nature and sometimes 
contradicted their other points in the same discussion, naturalness nevertheless 
occupied a significant place in their overall statements. Scientists were eager to answer 
the concerns of the public, to clear any misunderstanding that may exist, and to learn 
what more they could do to assuage their worries. 
 This positioning of the scientists at the roundtable, something that I have 
called a “Q&A” posture, is different from, if not separate from, the magisterial 
position of scientists as understood through the deficit model. Whereas in the deficit 
model scientists deem ignorance of science itself as the cause of public opposition to 
new science and seek to remedy this ignorance with scientific education, the scientists 
at the 112th Roundtable instead sought to answer whatever questions people might ask 
of them, regardless of whether those questions had any technical, scientific merit. Kim 
Jin-Soo went as far as to profess his willingness to spend sleepless nights fully 
discussing any and all concerns bioethicists may have about bioscience, until all 
questions are answered.156 
                                                 
156 This particular statement however is not new, and Korean scientists have been accused of promising 
to do so and then failing to deliver. Bang-Ook Jun, op. cit. p. 114. 
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 This eager ear of the scientists goes hand-in-hand with the deregulatory 
arguments: the Korean Bioethics and Safety Act is badly written primarily because it 
hinders the ability of science to answer questions, to acquire new knowledge that may 
be important in future decision-making. Whereas traditionally Korean scientists have 
accused bioethics of getting in the way of necessary progress that would benefit the 
state and nation, this new positioning instead argues that regulatory oversight is getting 
in the way of ethics, here represented by the naturalness concerns. By connecting 
“ethical” questions with scientific answers, scientists at the 112th Roundtable are 
attempting to bring bioethics into the aegis of scientific inquiry, so that ethical 
concerns would become cause for more research, not less. 
 The argument that regulation of research is counterproductive gains a new 
dimension in light of the prescriptions of Asilomar-in-memory, an idealized 
understanding of the Asilomar conference of 1975 and its immediate aftermath, where 
proper cooperation between scientists and the government resulted in what is 
understood to be a very successful management of the public’s concerns. In order for 
the newly re-positioned role of science as the answerer of questions to work, its 
capability to find answers must not be hindered. Even if it turns out that the ultimate 
decision of the public is to not adopt the new technology, until that decision can be 
made, science must be allowed to do everything in its power to find relevant answers. 
 This capacity to answer questions is uniquely reserved to the scientists and 
functions as a new pillar that supports the intellectual authority of science. As such, 
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even while science has yielded to the public the capacity to decide what questions are 
important, science is indispensable to the decision-making process, as without it 
decisions will have to be made blind. Scientists of the 112th roundtable accentuate this 
claim by referring to the 2015 International Summit and the subsequent 2017 NAS 
report Human Genome Editing as evidence of international recognizance of this essential 
role of science. The tripartite division of labour between answer-seeking science, 
concern-filled but curious public, and a mediating government must be maintained to 
ensure a fully functioning and progressive society. Because the Bioethics and Safety 
Act instead seeks to unilaterally control science, effectively shackling science in the 
name of the public, the Korean state will only end up preventing science from serving 
the public. Thus, the repositioning of the scientists in regard to naturalness-based 
concerns represent another attempt at rallying Korea under scientism. 
 On the other hand, this new positioning represents a shift away from the 
traditional dichotomy between the promotion of bioscience and biotechnology and 
the protection of human values. The legislative history surrounding the Bioethics and 
Safety Act is dominated by the permanent stand-off between these two concerns, 
which reconciliation was deemed impossible and legal proposals either struck a middle 
ground or discarded one concern in favour of the other. However, by attempting to 
answer naturalness-based concerns with scientific arguments (or ordinary arguments 
supported by the intellectual authority of the scientific community), the scientists at 
the 112th Roundtable Discussions can be said to have attempted to unite the two 
97 
 
positions into one, dominated by the authority of the scientists but still linked into a 
single narrative where scientific inquiry could satisfy both concerns. 
 The symbolic meaning of the Round Table in its original, Arthurian form is 
that there is no head in a round table, and thus all who sit at it are of equal standing. 
While the new positioning of the scientists in regard to naturalness-based arguments 
does not imply acknowledging moral authorities as being equal to scientific authorities, 
it still comes far from the previous mode of argumentation, which can be visualized 
as scientists and ethicists sitting at two separate tables facing each other. By adopting 
naturalness, a supposedly moral and non-scientific concern, as part of their collective 
argument for gene therapy research, the scientists have presented a way to frame the 
debate concerning gene therapy in a singular, unified imperative, instead of a conflict 
between two opposing positions. If this shift could be identified and acknowledged as 
such and nurtured into a new direction in debates regarding gene therapy in Korea, 
then I believe the 112th Roundtable could very well be the first step towards 
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유전자치료는 인간 유전자 조작의 당위성과 다양한 신체적, 사회적 부작용에 대한 
논란 속에서 찬반 입장 간의 첨예한 대립으로 둘러쌓여있다. 이전의 수단 보다 훨씬 
사용이 용이하고 정확한 3세대 유전자가위 “CRISPR-Cas9”의 발견과 관련 기술 
개발에 힘입어 세계 곳곳에서 유전자치료 연구가 진행 중인 오늘날 현행 
생명윤리안전법이 과도한 규제라고 판단한 한국의 일부 과학자들은 2017년 8월 
제 112회 한림원탁토론회에서 법의 완화를 주장하였다. 이들 과학자들이 자신의 
주장을 뒷받침하기 위해 내세운 주장 중에는 자연성에 기반한 논리도 포함되어 
있었는데, 본 연구는 대스턴(Lorraine Daston)과 비달(Fernando Vidal) 편저 “자연의 
윤리적 권위의 역사(Moral Authority of Nature)”의 해석에 동의하여 과학자들의 
자연성 기반 논리를 그 자체로 받아들이기 보다 관련된 다른 당위성과 논리적 
주장을 파헤칠 열쇠로 받아들였다. 본 논문은 과학자들의 주장 속에서 한국 
과학자들이 이해하고 있는 과학계와 일반 대중의 관계가 단순 부족모델 (deficit 
model)로 국한되지 않은 일종의 “문답형”의 관계라고 볼 근거가 있다고 주장한다. 
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